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PREFACE
I have had the privilege of working with Dr. Kenneth 
McColl in the field of duodenal ulcer disease. This 
collaboration has opened new aspects in the study of 
duodenal ulcer disease. I am indebted to Dr. McColl for 
his help and enthusiasm without which this work would not 
have been completed. This research has illustrated the 
important principles of scientific investigation.
Some of the work contained in this thesis has been 
published and reprints of these publications are submitted 
with the thesis. As the studies span several medical 
disciplines it has not been possible to complete them 
without the help of a number of colleagues and this is 
noted in the formal acknowledgements. The work has 
otherwise been carried out by myself.
The writing of this thesis is entirely my own work.
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Summary
Helicobacter pylori, a spiral shaped bacterium has 
recently been identified as one of the most important 
acquired factors in the development of duodenal ulcer 
disease.
This organism colonises the gastric antral mucosa, 
the body of the stomach and areas of gastric metaplasia in 
the duodenum. Infection of the gastric mucosa by H pylori 
is associated with the development of type B gastritis, 
but also with the development of gastric ulcers, and more 
strongly with the development of duodenal ulcers. Almost 
100% of individuals who have a duodenal ulcer have 
infection with H pylori.
Eradication of H pylori infection of the antral 
mucosa is associated with a fall in basal plasma gastrin 
concentration, the meal stimulated gastrin response and 
gastric acid output suggesting that infection with 
H pylori could lead to increased gastric acidity and cause 
the development of duodenal ulcer disease.
H pylori possesses unusually high urease enzyme 
activity. It has been suggested that the organism's 
urease activity could enable it to survive at low gastric 
pH by producing a cloud of ammonium which markedly raises 
the pH of the organism's environment and of the antral 
mucosal surface. The production of an alkaline 
microenvironment above the antral gastrin producing 
G cells could block the normal inhibition of gastrin 
release by gastric acid. An increased antral pH could
xi i
also promote the uptake of amines which promote gastrin 
release.
To examine the effects of infection on gastric 
ammonium concentration, plasma gastrin concentration and 
the creation of an alkaline microenvironment a series of 
studies were undertaken.
The effect of infection by H pylori on the 
concentrations of ammonium and urea in gastric juice was 
investigated. The effect of stimulating and inhibiting 
urease activity on gastrin release was investigated. The 
effect of the alkalinisation of the gastric antrum on 
gastrin release was also investigated. The effect of 
urease activity on the survival of H pylori was also 
studied in a series of in vitro environments.
Characteristic changes in the concentrations of 
ammonium and urea in gastric juice samples were 
demonstrated. In 27 subjects with duodenal ulcer disease 
the median (range) ammonium concentration was 3.4 mmol/L 
(1.0-13.0 mmol/L) when H pylori was present compared with 
0.64 mmol/L (0.02-1.4 mmol/L) following eradication. In 
16 subjects with chronic renal failure the median gastric 
juice ammonium concentration when infection was present 
was 20.0 mmol/L (13.9-43.1 mmol/L) compared with 4.8 
mmol/L (0.5-12.3 mmol/L) when infection was absent.
Gastric juice urea concentrations were lower when 
infection with the organism was present, median 0.8 mmol/L 
(0.5-2.9 mmol/L) compared with 2.1 mmol/L (1.0-3.7 mmol/L) 
after it had been eradicated. In subjects with chronic 
renal failure with infection the median gastric juice urea
xi i i
concentration was 2.2 mmol/L (0.5-8.7 mmol/L) compared 
with 13.8 mmol/L (5.4-20.8 mmol/L) when the organism was 
not present. The concentrations of urea and ammonium in 
the gastric juice samples did not clearly distinguish 
between the presence or absence of infection. When the 
urea/ammonium ratio was calculated all subjects with 
H pylori had a ratio of less than 0.8 while those free of 
infection had a ratio greater than 0.9. The urea/ammonium 
ratio could therefore be used to detect the presence of 
infection.
The effect of stimulating and inhibiting urease 
activity, on the plasma gastrin concentration was 
studied. Urease activity was stimulated by the 
intragastric infusion of dextrose solution containing 
urea. Subjects with duodenal ulcer disease who had proven 
infection with H pylori were studied. The same subjects 
acted as their own controls following eradication of 
H pylori. The intragastric infusion of 50 mmol/L urea in 
a dextrose solution increased the median gastric juice 
ammonium concentration from 2.3 mmol/L (1.3-5.9 mmol/L) to
6.1 mmol/L (4.2-11.9 mmol/L). There was no change in 
plasma gastrin concentration observed during infusion of 
urea either before or after eradication of the organism. 
Inhibition of H pylori urease activity was also 
attempted. The specific urease inhibitor, acetohydroxamic 
acid was administered as a single 750 mg oral dose to 6 
subjects who had duodenal ulcer disease. Inhibition of 
enzyme activity was demonstrated by the suppression of a 
14C-urea breath test administered shortly after the dose
xiv
of acetohydroxamic acid and reversion of the urea/ammonium 
ratio to that of non-infected subjects. No change in the 
basal plasma gastrin concentration or meal stimulated 
gastrin response occurred following inhibition of urease 
activity.
Some investigators have failed to observe a rise in 
plasma gastrin concentration in response to alkalinisation 
of the gastric antrum. This could explain why stimulating 
and inhibiting urease activity failed to alter plasma 
gastrin concentrations. The effect of alkalinisation of 
the gastric antrum on basal and meal stimulated plasma 
gastrin concentrations in 7 subjects with duodenal ulcer 
disease was therefore investigated.
Alkalinisation of the gastric antrum to a pH greater 
than 6.0 by infusion of citrate buffer pH 7.0 produced a 
similar increase in the integrated meal stimulated gastrin 
response both before, +73% (-63% to +500%), and after 
eradication of H pylori, +48% (-26% to +386%) (p=0.9, NS). 
Gastric alkalinisation by itself produced an increase in 
gastrin concentration both before (62 ng/L, 50-165 ng/L) 
and after (50 ng/L, 25-75 ng/L) (p<0.02) eradication of 
H pylori. These experiments demonstrated that if 
alkalinisation of the gastric antrum resulted from 
H pylori urease activity then stimulation and inhibition 
of urease activity should have altered plasma gastrin 
concentration especially as subjects with the infection 
were more responsive to alkalinisation.
Although the in vivo studies demonstrated that the 
urease activity of H pylori did not alter plasma gastrin
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concentration through alkalinisation of the gastric antrum 
its urease activity has been shown to protect the organism 
from acid environments in vitro. In vitro studies of the 
effect of pH, urea concentration and inhibition of urease 
activity on survival of the organism were therefore 
conducted.
In a pilot study H pylori was inoculated into a 
series of 0.2 mol/L citrate buffer solutions with pH 
ranging from 1.5 to 7.0, containing 50 mmol/L urea. At 
the end of a 60 min incubation 89.9% of the initial 
inoculum survived at pH 2.0, 50.3% at pH 4.0 and 91.3% at
pH 7.0. At pH 5.0 and pH 6.0 there was no survival of the
organism.
The initial urea concentration in pH 6.0 citrate 
buffer was a factor in the survival of the organism. The 5 
min survival of H pylori decreased from 121% (69-148) in 
the absence of urea to only 9% (0-22%) with 50 mmol/L urea 
(p<0.01). The addition of the urease inhibitor
hydroxyurea to pH 6.0 buffer solution containing 10 mmol/L
urea reduced the 5 min ammonium concentration from 2.5 
mmol/L (1.9 -7.6 mmol/L) to 1.29 mmol/L (1.03-1.53 mmol/L) 
(pcO.001), but increased survival of the organism from 22% 
(10-30%) to 35% (range 30-50%), demonstrating that the 
destruction of the organism was urease dependent.
Enhanced survival of the organism at low pH was also 
urease dependent as the addition of hydroxyurea to citrate 
buffer pH 3.0 containing 10 mmol/L urea resulted in the 
destruction of the organism.
Ammonium production was also a factor in the 
destruction of H pylori at pH 6.0. The median recovery of
xvi
ammonium was 27% (7-94%) with an initial urea 
concentration of 1 mmol/L, and only 3% (2-22%) at 50 
mmol/L. The reduced recovery of ammonium was associated 
with the fall in the 5 min survival of the organism. 
Citrate buffer was also required for the destruction of 
the organism as the 5 min survival improved from 29% 
(10-64%) in this buffer with 30 mmol/L urea to 80% 
(26-160%) in acetate, and 100% (72-128%) in phosphate 
buffers with 30 mmol/L urea (p<0.01). The addition of the 
precursors for ammonium metabolism, isocitric acid and 
alpha ketoglutarate, to buffer solutions containing 50 
mmol/L urea also enhanced the survival of the organism.
These studies indicated that the in vitro destruction 
of the organism was due to intra-cellular accumulation of 
ammonium and depletion of alpha ketoglutarate.
In conclusion in vivo studies demonstrated that 
alkalinisation of the gastric antrum by H pylori urease 
activity was not responsible for the increased plasma 
gastrin concentrations found in infected individuals. The
in vitro studies demonstrated that uncontrolled urease 
activity could result in the destruction of H pylori. If
this could be harnessed then it may be of great 
therapeutic potential.
xvii
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CHAPTER 1
DUODENAL ULCER DISEASE
DUODENAL ULCER DISEASE
Peptic ulcer disease and in particular duodenal ulcer 
disease are major causes of illness in the Western world. 
Autopsy surveys show that more than 20% of all men and 10% 
of all women have evidence of past or present peptic ulcer 
disease (1). Estimation of the prevalence of peptic 
ulcers at autopsies may also significantly underestimate 
the disease as detection of ulceration depends on the 
demonstration of an active ulcer or of scarring as a 
result of the healing of an ulcer (2). Some ulcers may 
heal without scarring and so escape detection.
It seems likely that the prevalence of duodenal ulcer 
which was becoming commonly described between 1890 and 
1910 rose between 1900 and 1960 (1-4). Initially the 
prevalence of duodenal ulcer disease may have risen 
rapidly but for the last 20 years of the period may have 
risen more slowly. Recently epidemiological data would 
suggest that duodenal ulcer prevalence has fallen in 
younger age groups but has remained the same in the 
elderly, and especially in women.
While the exact aetiology of duodenal ulceration 
remains unknown some aetiological factors have been 
identified.
1
Acid
Some patients with duodenal ulcer disease may have 
increased gastric acid secretion although there is overlap 
between gastric acid output of subjects with duodenal 
ulcer disease and those without ulcers (5,6). The 
response of peptic ulcers to treatment with agents which 
block the secretion of acid such as the gastric proton 
pump inhibitors (Omeprazole, Astra, Bucks, UK) and H^ . 
Receptor blockers (Ranitidine, Glaxo, UK) also indicates 
the importance of gastric acidity in the development and 
persistence of duodenal ulcers.
Pepsin
It was suggested by Schwartz in 1910 that both acid 
and peptic activity were required for the development of 
duodenal ulcers (7). The role of gastric peptic activity 
in the development of duodenal ulcers is not yet 
established but raised serum pepsinogen I concentrations 
are a marker for peptic ulcer disease (7,8). Increased 
pepsinogen I concentrations inherited in an autosomal 
dominant pattern are also associated with duodenal ulcer 
disease.
Motility
Abnormalities of gastric emptying are seen in some 
patients with duodenal ulcer disease (9). The importance 
of this in the development of ulcers is not known.
Mucus
Patients with peptic ulcer disease have been shown
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to have altered gastric and duodenal mucus (10). They 
have increased portions of low molecular weight dextrans 
which are associated with weaker mucus and decreased 
hydrophobicity (11).
Bicarbonate
Decreased secretion of duodenal and pancreatic 
bicarbonate and impairment of the duodenal mucosal pH 
gradient have been demonstrated in patients with duodenal 
ulcers (12). These abnormalities may increase the 
susceptibility of the duodenal mucosa to damage from 
gastric acid.
Cigarette Smoking
Cigarette smoking has been linked to the development 
of duodenal ulcer disease. A dose dependent effect on the 
rate of ulcer relapse has been demonstrated (13). Other 
effects of cigarette smoking include acceleration of 
gastric emptying of liquids, increased duodenal bile 
reflux, inhibition of pancreatic bicarbonate secretion and 
decreased duodenal pH (14-17).
Non-steroidal anti-inflammatory agents (NSAIDS)
The use of non-steroidal anti-inflammatory agents may 
result in acute mucosal lesions such as haemorrhages and 
erosions or the development of chronic ulceration. NSAIDS 
inhibit the production of prostaglandins which have been 
shown to be necessary for the production of mucus and 
secretion of bicarbonate and may regulate gastric blood 
flow (18). The inhibition of these protective mechanisms 
is likely to be the mechanism through which NSAIDS are 
involved in the development of peptic ulcer disease.
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Helicobacter pylori
Recently, infection of the gastric antral mucosa (Fig 
1.1) and areas of gastric metaplasia in the duodenum have 
been associated with the development of duodenal ulcer 
disease. Infection with H pylori has also been associated 
with increased plasma gastrin concentrations, meal 
stimulated gastrin response and gastric acid output 
(19-26), serum pepsinogen I concentrations (23), and 
alterations to gastric mucus (27-31) as well as gastric 
and duodenal inflammation. Infection by this organism has 
the potential to explain many of the pathophysiological 
changes associated with the development of duodenal ulcer 
disease and the observed change in prevalence of duodenal 
ulcer disease this century.
4
Helicobacter pylori colonising the gastric antral mucosal surface. 
Haematoxylin and eosin stain, magnification xlOOO
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HELICOBACTER PYLORI AND ITS UREASE ACTIVITY
IN THE DEVELOPMENT OF DUODENAL ULCER DISEASE
2.1 Initial Isolation of Helicobacter pylori
Helicobacter pylori was originally isolated by Warren 
and Marshall in i982 (32,33). Since 1980 Warren had 
observed curved and spiral campylobacter-like organisms in 
gastric biopsy specimens. These organisms stained well by 
the Warthin-Starry method but poorly with the haematoxylin 
and eosin stain (32). A prospective study was initiated 
which resulted in the isolation of the organism by culture 
of biopsy material from patients with chronic gastritis 
(32-36). Following discovery, the organism was initially 
classified as Campylobacter pyloridis but was later 
reclassified as Campylobacter pylori (37). Further 
studies of the organism's ribosomal RNA, its 
ultrastructure and fatty acid composition showed that it 
did not belong to the genus Campylobacter (38-42). In 
1989 it was reclassified as Helicobacter pylori (43).
There had been evidence of spiral bacteria colonising 
the gastric mucosa since 1938, when Doenges published a 
study showing that histological examination of the 
postmortem stomach demonstrated the presence of 
'spirochaetes' on the gastric mucosa in 43% of 242 
postmortem specimens (44). This original observation was
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repeated by Freedberg and Barron in 1940 when they found 
that 37.5% of 35 gastric specimens they examined contained 
1spirochaetes*(45). In 1975 Steer observed bacteria close 
to the surface of the gastric mucosa and associated with 
gastritis (46,47). The organisms were also spiral but 
this was not commented on in the report.
Steer later produced a further study with scanning 
electron microscopic pictures demonstrating large numbers 
of curved and spiral bacteria on the surface of gastric 
type epithelial cells in the prepyloric area of the 
stomach and in areas of gastric metaplasia in the duodenal 
bulb but not associated with the intestinal type of 
epithelial cells (48). Other studies of gastritis had 
also demonstrated curved bacteria associated with the 
surface of the mucosal cells but never penetrating the 
cells (49,50).
Indirect evidence of bacterial colonisation of the 
gastric mucosa came from studies demonstrating the 
presence of urease activity in the stomach (51-53). That 
this urease activity might be bacterial in origin was 
suggested originally in 1959 by Lieber and Lefevre (52). 
Studies using germ free animals (54) in 1968 demonstrated 
that gastric urease activity was bacterial in origin 
because it was not found in germ free animals. Bacterial 
urease activity in the stomach was not linked to the 
reports of spiral bacteria in the stomach until 1984. The 
original description of Helicobacter pylori (36) reported 
that it was urease negative but this was later corrected 
as the organism possesses abundant urease activity which
6
is now considered to be one of its unique features 
(55-57).
2.2 Detection of Helicobacter pylori infection
Helicobacter pylori was originally detected by 
microscopic examination of histologically stained duodenal 
and gastric biopsies. The organism is often visible on 
routine haematoxylin and eosin stained preparations.
Other stains have been used to help make visualisation 
easier including the Warthin-Starry silver stain, which 
results in silver deposition over the organism (33,34).
The Giemsa (58), Brown-Hopps (59), Carbolfuchsin (60) and 
Acridine orange (61) stains have also been used. None of 
these stains are specific for the micro-organism. 
Examination of biopsy specimens is not a specific method 
of detecting the organism. Observation of the organism's 
characteristic appearance at microscopic examination does 
not exclude the possibility of other organisms or 
artefacts (62-64).
The standard by which other methods for the detection 
of infection with H pylori are assessed remains the 
bacterial culture of the organism. The bacterium 
originally proved difficult to isolate and was not 
identified until culture plates were left for a prolonged 
period (33,34). The cultures required to be incubated 
micro-aerophilically at 37°C for 3-4 days before the 
organisms became visible. The organism was originally 
isolated using chocolate agar (33,34).
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The sensitivity of both bacteriological culture of 
and histological examination of biopsies depends on the 
colonisation of the antral mucosa by the bacterium. False 
negative results could occur when the distribution of 
H pylori was patchy. In one study of multiple gastric 
biopsies from 50 patients false negative antral biopsies 
occurred infrequently (65). Histological examination of 
biopsies from which the organism had been isolated found a 
3% rate of false negative biopsies. The collection of two 
to four antral biopsies at endoscopy is usually therefore 
considered sufficient to eliminate sampling error although 
this view is not universally accepted (65-67).
Other methods of detecting the micro-organism depend 
on its urease activity. The rapid urease test (CLO Test) 
has been used to detect urease activity in antral biopsy 
specimens (68). In this test the biopsy is inserted into 
a buffered gel. The gel also contains urea and phenol 
red, which is a pH indicator. Initially the gel is 
buffered to an acidic pH at which phenol red gives a 
yellow colour. When a biopsy containing urease activity 
is inserted the ammonium produced by the enzyme produces 
an increase in the pH of the gel and results in a change 
in colour from yellow to pink when the pH rises above 
6.0. This test takes a minimum of 3 h when incubated at 
30°C before the colour change becomes visible. Some 
biopsies may take up to 24 h before the colour change 
becomes visible. A small number of false negative 
reactions may occur with this test (69).
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A number of variations on this principle have been 
described (70,71). These methods use indicator dyes in 
buffered solutions to identify specimens which contain 
urease activity. The reagents used in these tests are 
easily obtained. Advocates of these tests suggest that 
they are suitable for the rapid side room detection of the 
micro-organism although there have been no reports of the 
sensitivity or specificity of these methods. The 
advantage of these rapid urease tests is that the H pylori 
status of patients may be obtained in a few hours compared 
with 24 h for histology or 3-4 days for microbiology.
The 14C-urea breath test detects H pylori by the 
production of radiolabelled 14C02 as a result of its 
urease activity (72,73). A dose of 0.4 Mbq, of 14C 
labelled urea is administered following a liquid meal 
which is used to delay gastric emptying. A portion of the 
labelled C02 is exhaled in the breath. Breath samples 
are therefore collected every 10 min during the 2 h after 
the radiolabel is ingested. The exhaled CO?., is trapped 
by hyamine contained in a vial through which the exhaled 
breath is bubbled. Scintillant is added to the trapped 
breath CO?, samples and the radioactivity counted. The 
activity is expressed as the percentage of the 
administered dose per millimole of expired C02 
multiplied by body weight to allow for endogenous C02 
production. The 14C-urea breath test is a very 
sensitive and reproducible method of determining the
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H pylori status of a patient. The disadvantage of this 
test is that it takes at least 24 h before a result is 
available. In addition a dose of radioactivity has to be 
administered to the patient. Administration of the 
radiolabel may make the test unsuitable for repetitive 
investigation and the investigation of children or 
pregnant women.
A 13C-urea breath test has also been developed.
The principle is the same as the 14C-urea breath test 
except that a mass spectrometer is required to detect the 
exhaled 13C labelled C0Z (74). This method of 
detecting the micro-organism avoids the use of a 
radiolabel and is as sensitive and specific as the 
14C-urea breath test. The disadvantage is that it 
requires a mass spectrometer which may not be available 
outside specialist centres.
Serological tests have also been developed for the 
detection of H pylori as infection is associated with 
serological conversion (75-79). Detection of infection by 
serological methods has the advantage that special 
precautions prior to collection of the sample are not 
required. One study suggested that serological testing 
could reduce endoscopy workload (79). However, during the 
acute phase of the infection, the organism may not be 
detected by this method. In addition, serological 
evidence of infection may persist after the organism has 
been eradicated (80). While serological detection of 
H pylori has some advantages over more invasive
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investigations the sensitivity and specificity of serology 
when compared to the 14C-urea breath test was only 83% 
and 68% in one study of elderly patients (81). It was 
suggested that this may have been due to reduced immune 
competence in the elderly.
Other investigators have suggested that differences 
in specificity of antibodies in enzyme linked 
immunosorbent assays for H pylori may result in the 
reduced sensitivity and specificity of the serological 
tests compared with other methods (80,82-85). This 
discrepancy between some serological tests may be due to 
differing sensitivities to different strains of H pylori 
(85).
The DNA polymerase chain reaction has also been used 
to detect the presence of H pylori DNA in gastric biopsy 
samples (86). This method of detecting the organism gives 
high specificity and sensitivity since the polymerase 
chain reaction may be used to amplify small amounts of DNA 
present in biopsy samples. The disadvantage of this 
method of detecting the organism is that it requires a 
high degree of technical skill with DNA methodologies 
which may not be available in district general hospital 
laboratories.
The development of so many methods for the detection 
of the micro-organism suggests that none are ideal. The 
gold standard of detection remains the culture of the 
organism from a biopsy. The 14C-urea breath test may be 
as specific as culture of the organism and is potentially 
more sensitive, more rapidly completed and less invasive
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as the collection of a biopsy is not required. The rapid 
chemical tests based on urease activity are the quickest 
and most convenient method, although quantitation of 
infection with these tests is not possible and a biopsy 
still needs to be collected. Serological identification 
of infection would appear to be a convenient method but 
has been shown to be associated with a sufficient 
incidence of false positives and false negatives to 
potentially make it one of the least reliable methods of 
detecting current infection with the micro-organism.
Two methods of detecting the organism are currently 
advocated in most studies. With the development of 
suitable treatments which result in the eradication of the 
organism detection of infection in asymptomatic 
populations will become essential and will either result 
in increased usage of these methods for detection of 
infection with Helicobacter pylori, or the development of 
other sensitive and specific tests of the presence of the 
organism.
2.3 Epidemiology of Helicobacter pylori infection
The most extensively studied populations with respect 
to the prevalence of Helicobacter pylori are those from 
Western Europe, North America, New Zealand, and 
Australia. The organism has been identified in 
association with type B chronic gastritis from most 
nationalities and populations.
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Studies of the prevalence of infection have used a 
variety of methods of identifying the organism in a wide 
range of populations.
Autopsy examination of the histological appearance of 
the gastric mucosa, and tests for urease activity in small 
numbers of individuals has demonstrated infection in 60% 
of Polynesians and 20% of Caucasians (87). Endoscopic 
collection of biopsy specimens from asymptomatic young 
adult medical students in the Netherlands showed an 
infection rate of 25% (56). A prevalence of 20% was found 
in a similar study in the United States of America (88). 
The prevalence of infection detected using the 13C-urea 
breath test in Americans rose from 24% in the age range 
20-39 years to 36% in the age range 40-50 years and to 82% 
in the age range 50-84 years (89). Serological testing 
has also been used and this has again demonstrated an 
increase in prevalence with age (78). Using serological 
testing the infection rate for male children was 11% and 
for female children was 5%. For adults less than 30 years 
of age the rate was 23% for males and 5% for females.
While for adults older than 30 years of age 29% of males 
and 25% of females had the infection demonstrated by 
serology. The increase in the rate of infection with age 
has also been reported in other surveys in which samples 
from blood donors were used for serological testing or 
endoscopic biopsies collected for histological examination 
(90-92).
The prevalence of H pylori specific IgG has also been 
investigated in a group of North Western Australian
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Aborigines (93). It has been discovered that this human 
population rarely develops duodenal ulcers (94). The 
prevalence of infection in this population was 1% or less, 
suggesting that infection is not only important for the 
persistence of the ulcer but also in the development of a 
duodenal ulcer.
The available evidence from studies of seropositivity 
for H pylori specific IgG, 13C-urea breath test, and 
examination of biopsy material collected at endoscopy or 
postmortem indicates that the infection is commonly 
present especially in older groups when over 80% of the 
population may be infected. The prevalence of infection 
also rises with age. These epidemiological studies have 
not demonstrated a relationship between those who only 
have the infection and those who go on to develop duodenal 
ulcers. Other factors such as cigarette smoking, peptic 
activity, and genetic inheritance may also help determine 
those H pylori positive individuals who go on to develop 
duodenal ulcers.
2.4 The effects of acute infection with Helicobacter
pylori
The effects of acute infection with the organism have 
been documented in two healthy volunteers, in one research 
fellow who developed the infection while engaged in 
research in a gastroenterology unit, and in volunteers in 
two other studies who probably contracted the infection
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accidentally as a result of a failure to sterilise gastric 
pH electrodes between subjects (95-100). The symptoms 
reported were of mild epigastric pain or discomfort along 
with epigastric fullness, malaise, headache, halitosis and 
vomiting. The symptoms occured 2-7 days after infection 
and lasted for 1-7 days. One volunteer experienced severe 
vomiting and symptoms consistent with bowel obstruction of 
which there was no sign on erect and supine abdominal 
X-ray (96). Gastric biopsy specimens from these subjects 
showed an active chronic gastritis with polymorphonuclear 
inflammation in the antrum and the presence of H pylori 
(98).
Transient hypochlorhydria was observed in one 
volunteer, the research fellow, and 9 of the 17 subjects 
in another study who had been infected with the organism 
(96,97,100). The gastric juice pH of the other volunteer 
who ingested the organism was not measured but it was 
reported that his vomitus did not taste acid, and was not 
acid on testing with litmus paper (95). The 
hypochlorhydria appears to be transient but may persist 
for up to 235 days (median 112, range 53-235 days) before 
resolving (97). Maximum depression of peak acid output 
was also noted to parallel the severity of the 
histological gastritis in one study (97). Chronic 
gastritis and infection with H pylori persisted in one 
volunteer despite treatment with bismuth subsalicylate 
aimed at eradicating the infection.
These studies demonstrate that when H pylori
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colonises the gastric mucosa it causes histological 
gastritis and symptoms associated with this infection.
Once established the organism can persist and may cause a 
chronic gastritis despite attempts to eradicate it. A 
fall in gastric juice ascorbic acid concentration was 
observed in samples from the research fellow who became 
infected (100). The reduction in gastric juice ascorbic 
acid was attributed to an inhibition of the secretion of 
ascorbic acid into the gastric juice.
2.5 Helicobacter pylori and disease in children
Infection of the gastric mucosa by Helicobacter 
pylori in children is associated with an antral gastritis 
(23,101,102). Recurrent abdominal pain is the common 
presenting symptom in children (101,102). The pain may be 
epigastric or periumbilical. Vomiting and haematemesis 
may also occur.
Infection of children with H pylori is often found in 
association with gastric or duodenal ulcers 
(101,103,104). Up to 29% of children infected with the 
organism may have duodenal ulcers. Recurrence of peptic 
ulcers in infected children following healing with H ?. 
receptor antagonists occurs as it does in adults. Besides 
the development of duodenal ulcers children with this 
infection have also presented with iron deficiency anaemia 
(105) and protein losing enteropathy (106). Infection of 
children with H pylori has also been implicated in the 
development of malabsorption syndromes in Third World
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countries, and East Africa (107).
Infection with H pylori may therefore occur at any 
age. It is typically associated with antral gastritis and 
duodenal ulcers in both children and adults.
2.6 Chronic Gastritis and Helicobacter pylori 
Persistence of infection of the stomach by 
Helicobacter pylori results in persistent gastritis 
(97-100). The multiple appearances of gastritis has made 
classification of chronic gastritis difficult. Several 
systems of classification have been proposed (108-110). 
When chronic gastritis is graded on the basis of the 
presence or absence of glandular atrophy then in the 
absence of the loss of glands it is termed chronic 
superficial gastritis and with the loss of glands chronic 
atrophic gastritis (108). Chronic atrophy of gastric 
glands is usually associated with pernicious anaemia but 
not invariably so (111). Autoimmune gastritis associated 
with pernicious anaemia has also been termed type A 
gastritis (110).
Type A Gastritis
Type A gastritis (body-mucosa) affects the body of 
the stomach and is associated with parietal cell 
antibodies and achlorhydria (109). Only the acid 
producing parietal cells of the body and fundus are 
affected while the mucous secreting epithelial cells 
lining the entire stomach are not damaged. The gastric
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antrum is also spared. The end result of this severe form 
of gastric atrophy may be intestinal metaplasia. Type A 
gastritis may be asymptomatic.
A reduced prevalence of H pylori in body and antrum 
of the stomach of individuals with type A gastritis was 
found when they were compared with age sex matched 
controls with peptic ulcer (112). A similar study 
demonstrated that pylori was rarely present in patients 
with type A gastritis even when the gastric antrum was 
involved, suggesting that the organism is not associated 
with the development of this type of gastritis (113).
Reflux Gastritis
Persistent injury to the surface epithelium of the 
stomach due to enterogastric reflux following gastric 
surgery is characterised by compensatory foveolar 
hyperplasia and a vascular and exudative response 
evidenced by capillary dilatation, congestion and lamina 
propria oedema (114). Increased numbers of smooth muscle 
fibres and collagen bundles may appear in the lamina 
propria (114 ) .
Agents which injure the gastric epithelial surface 
and cause this type of gastritis include bile acids and 
lysolecithin (115). These agents damage the mucous 
barrier. Exposure of the mucosal surface to bile, a 
biological surfactant also leads to the degranulation of 
mast cells and a vascular response mediated by histamine
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which causes further damage to the surface epithelium 
(115). Other chemical insults to the gastric mucosa such 
as salicylates and other non-steroidal anti-inflammatory 
agents may also cause the histological appearances of 
reflux gastritis (116).
Reflux gastritis has not been associated with 
H pylori (117). The surgical treatment of duodenal ulcers 
by gastroenterostomy or other procedure that causes 
gastroduodenal reflux results in a change of the 
histological appearance of gastritis from that associated 
with H pylori to that of reflux gastritis (117). The 
toxicity of bile acids to H pylori may cause the 
elimination of the organism (118). This could explain the 
change in histological appearance of gastritis.
Lymphocytic Gastritis
Lymphocytic gastritis is similar to active chronic 
superficial gastritis but is identified by the 
infiltration of the surface and foveolar epithelium with 
lymphocytes (119). At endoscopy nodular prominence of the 
gastric mucosa with the nodules being surmounted by 
shallow apthoid erosions may be seen. These changes are 
usually confined to the body of the stomach. Only small 
numbers of patients with this type of gastritis have been 
found to be infected with H pylori (120,121).
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Type B Gastritis
Type B gastritis typically affects the mucous 
secreting epithelium of the gastric antrum but may also 
involve the acid secreting part of the stomach. It is one 
of the commonest forms of gastritis and occurs in 78%-100% 
of patients with duodenal ulcers (35,66,76,122-131). 
Dyspeptic patients with gastric ulcers also tend to have 
type B gastritis that is histologically the same as that 
found in patients with duodenal ulcers (122). Type B 
gastritis has been shown not to be related to duodenal 
gastric bile reflux which was at one time thought to be 
the cause of this type of gastritis. It is highly 
associated with H pylori infection (66,76,122-131). In 
type B gastritis the organism is not confined to the 
antral area but may also be found in the body of the 
stomach. The natural history of type B gastritis is not 
known but it is thought that it may commence as a diffuse 
inflammation in both the body and antrum of the stomach.
It may then remain as a static chronic superficial 
gastritis showing no tendency to progress. In one study 
of 67 positive patients, 13 became negative on follow-up 
from one month to 10 years, while 3 of the 41 initially 
negative became positive (129). Loss of infection was 
associated with the development of intestinal metaplasia 
or of lymphocytic gastritis.
The prevalence of type B (antral) gastritis increases 
with age and this again suggests that once H pylori has
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colonised the gastric mucosa it may persist for life 
(80,89,92). Finally, eradication of antral infection with 
H pylori using triple therapy which combines a course of 
tripotassium dicitrato bismuthate (DeNol), metronidazole 
and amoxycillin, results in resolution of the gastritis 
indicating that the organism is the cause of the gastritis 
(23).
Infection with H pylori has been shown to be closely 
associated with type B chronic antral gastritis. The 
development of type B antral gastritis has also been shown 
to be closely associated with the development of duodenal 
ulcer disease occurring in up to 100% of individuals with 
duodenal ulcers. Persistent infection of the gastric 
antral mucosa by H pylori may therefore cause or sustain 
the development of duodenal ulcers.
2.7 Helicobacter pylori, Gastric Ulcers and Gastric
Carcinoma
Infection of the gastric mucosa with Helicobacter 
pylori results in the development of chronic type B 
gastritis. Prior to the discovery of H pylori an 
association had been found between the development of 
gastritis of a typical type B chronic gastritis pattern 
affecting the antrum and with the development of gastric 
ulcers irrespective of the site of the ulcer (132-134). 
While almost all patients with duodenal ulcers have 
infection of the gastric antrum with H pylori only 70% of 
patients with gastric ulcers can be shown to have 
infection with the organism (35,122). A number of
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other factors in addition to Helicobacter pylori have also 
been found to cause the development of gastritis including 
cigarette smoking, ingestion of nonsteroidal 
anti-inflammatory agents and duodenogastric reflux 
(13,18,135-137).
Examination of the histological type of gastritis 
associated with the development of gastric ulcers in 
pylori negative patients has demonstrated that most have 
features of reflux gastritis (122,138). Biliary reflux is 
harmful to pylori and the development of this is 
associated with loss of infection (117).
A multifocal chronic atrophic gastritis is considered 
to be a precursor lesion in the path of the development of 
gastric carcinoma (109). Carcinomas which develop from 
this type of lesion tend to be of the 'intestinal * or 
'expansive' type. H pylori does not colonise intestinal 
epithelium but its presence in surrounding areas of 
gastritis has recently been associated with the 
development of intestinal metaplasia of the antrum (139). 
An association between the development of gastric 
carcinoma and infection with H pylori demonstrated by the 
presence of IgG antibodies to the organism has also been 
recognised (140). This study suggested that between 35% 
and 55% of all cases may be associated with this 
infection. Despite this, another recent study of gastric 
carcinoma in two high risk populations demonstrated that 
while infection with the organism may cause irritation of
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the gastric mucosa it did not appear to have a causative 
role (141). Type A atrophic gastritis and reflux 
gastritis have both been associated with the development 
of gastric carcinoma and are not associated with infection 
with H pylori (109,117).
Two groups of agents are recognised in the 
development of cancer. These are initiators and 
promoters. Initiators cause the pre-requisite cellular 
genetic or metabolic changes for the development of cancer 
over a short period of exposure. The initiator may be a 
complete carcinogen and repeated exposure result in the 
development of cancer. As prolonged infection with 
H pylori frequently occurs without the development of 
malignancy it is unlikely that H pylori is an initiator. 
Promotors increase the chance of the development of 
malignancy through repeated exposure to cells already 
exposed to an initiator. The chronic irritant and 
inflammatory effects of infection with H pylori might 
promote the development of malignancy.
In addition, gastric juice vitamin C concentrations 
are also reduced when H pylori infection is present. It 
has been suggested that gastric juice vitamin C protects 
the gastric mucosa from the carcinogenic effects of 
oxidising agents such as nitrites and free radicals 
(100,142,143). The fall in gastric juice vitamin C 
following infection could also explain the association 
with the development of gastric carcinoma. These effects
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could explain the close association of H pylori with 
chronic gastritis and its association with the development 
of gastric carcinoma.
2.8 Helicobacter pylori and duodenal ulcer disease
There is a clear association between the development 
of duodenal ulcer disease and infection of the antral 
mucosa by Helicobacter pylori. This might merely indicate 
that the organism is a marker for the development of 
duodenal ulcer disease. The presence of other factors 
associated with the development of a duodenal ulcer might 
themselves make colonisation of the gastric mucosa easier 
for H pylori. Recently, eradication of infection with 
H pylori has been shown to reduce the ulcer relapse rate 
following healing from 80% to 20% or less (144-146). In 
addition reports of H pylori negative individuals with 
duodenal ulcers usually identify other aetiological 
factors, such as the use of non-steroidal 
anti-inflammatory agents or associated pancreatitis 
(35,147). Recurrence of the ulcer following eradication 
of the organism is usually associated with re-infection. 
Studies of H pylori cultured from individuals with 
re-infection suggest recrudescence of infection with the 
original organism rather than the acquisition of a second 
infection with H pylori (148). This clear association 
between the development of duodenal ulcers and infection 
with H pylori and the healing of ulcers following the
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eradication of infection by H pylori demonstrates that 
the organism is likely to be directly involved in the 
development of, and the relapse of duodenal ulcers. 
Although the organism is closely associated with the 
development of duodenal ulcers the means by which it 
causes the development of an ulcer remains unclear 
especially as the organism predominantly colonises the 
gastric mucosa and does not colonise the intestinal 
mucosa. In some individuals H pylori does colonise the 
duodenum (147).
2.9 Helicobacter pylori and duodenitis
Individuals from whom the organism has been isolated 
from the duodenum have histological evidence of duodenitis 
with areas of gastric metaplasia. Gastric metaplasia in 
the duodenum is common in normal individuals (149).
Gastric epithelium may develop in the duodenum in two 
circumstances. It develops either as an area of 
heterotropic gastric body type mucosa or as a metaplastic 
change of an area of duodenal mucosa (149,150). Gastric 
heterotropia is characterised by islands of fully 
developed fundic mucosa including parietal and chief 
cells. It is found in 1-2% of duodenal biopsies 
(149,150). It is considered to be congenital in origin 
and is not associated with duodenitis.
Gastric metaplasia develops as small foci of gastric 
epithelial cells on the tips of villi. It is extensive in 
patients with duodenal inflammation and ulceration
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(150-156). It occurs in up to 100% of individuals with 
duodenal ulcer disease. H pylori has been identified 
histologically in areas of gastric metaplasia in only 55% 
of duodenal biopsies (150). This may be due to the patchy 
nature of the lesion.
Gastric metaplasia is thought to represent a response 
to injury of the duodenal mucosa. Animal experiments have 
shown that gastric metaplasia may develop in response to 
duodenal hyperacidity in rats, pigs and monkeys 
(157-160). It may also occur during the healing of 
surgically induced defects of the duodenal mucosa in cats 
(161). In man gastric metaplasia is found extensively in 
patients with the Zollinger Ellison syndrome (162) and in 
individuals with a low fasting gastric juice pH (149).
Its development has also been correlated with increasing 
acid output (149,163,164). In addition it has not been 
found in individuals with atrophic gastritis. Acid 
secretion in patients with duodenal ulcers may range from 
normal to increased levels (5,6,19). In patients with 
duodenal ulcers gastric metaplasia of the duodenum could 
therefore represent a response to an increased acid 
load.
Once gastric metaplasia of the duodenum has developed 
H pylori may colonise the areas of gastric epithelium in 
the duodenum but it does not colonise the intestinal 
mucosa. Areas of intestinal metaplasia in the stomach are 
also spared by the organism (110,156). Although H pylori 
does not invade metaplastic gastric mucosa in the duodenum
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it causes an active duodenitis (149.154). Immune 
responses to the organism have been demonstrated and 
putative bacterial exotoxins have also been reported 
(165-176). Infection of metaplastic gastric mucosa by the 
bacterium despite the absence of invasion can result in 
the development of an immune response and could therefore 
account for the associated inflammation (165,169,170).
Gastric metaplasia may develop in response to 
increased gastric acidity in patients with duodenal ulcer 
disease. The development of gastric metaplasia would 
allow colonisation of the duodenum by H pylori. This 
could result in the development of duodenitis. If 
colonisation of the gastric antral mucosa by H pylori
leads to the development of gastric metaplasia of the
duodenum then colonisation of the antrum would be the 
primary event in the development of duodenal ulcer 
disease.
2.10 How Helicobacter pylori Infection might cause
Duodenal Ulcer Disease
Infection with Helicobacter pylori results in 
colonisation of the gastric antral mucosa, the development
of chronic type B gastritis and colonisation of areas of
gastric metaplasia in the duodenum. These observations do 
not establish how the organism may cause duodenal ulcer 
disease.
A number of hypotheses have been proposed to explain 
how colonisation of the gastric antral mucosa or
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colonisation of the duodenal mucosa by this organism could 
lead to the development of peptic ulcers. It has been 
suggested that colonisation of areas of gastric metaplasia 
in the duodenum and the associated inflammation may be a 
key event leading to ulcerogenesis. Abnormalities of the 
duodenal mucosa also persist after healing of a duodenal 
ulcer (177-179). If this is the case then the 
colonisation of the duodenal mucosa may not be essential 
for the development of duodenal ulcers. If colonisation 
of the gastric antral mucosa by H pylori leads to the 
development of gastric metaplasia of the duodenum then 
colonisation of the antrum will be the primary event and 
colonisation of gastric metaplasia in the duodenum a 
secondary event in the development of duodenal ulcer 
disease.
It has been suggested that a vigorous immune response 
to infection of the gastric antrum might result in damage 
to the duodenal mucosa and the development of ulcers.
H pylori can initiate an inflammatory reaction as 
demonstrated by the expression of Class II transplantation 
antigens on epithelial cells and increase numbers of 
T-lymphocytes (169). Studies using a mouse model have 
shown that infection with H pylori can induce antibodies 
which cross react with human gastric mucosa (176). 
Antibodies which cross react with duodenal mucosa have not 
been reported.
Serological studies show that infection with the 
organism appears to be widespread and increases with age
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(90,91). One study has also shown that the serological 
response to infection may diminish with age (81), although 
the prevalence of duodenal ulcers in the elderly may have 
risen slowly over the past 20 years. Other studies have 
shown that while 49% of individuals studied had 
serological evidence of a current immune response to 
H pylori only 24% had evidence of a current infection. 
These observations may indicate that a failure to 
eliminate H pylori may be more important in ulcerogenesis 
than the development of an immune response to infection 
(80).
H pylori produces a number of toxins and other 
substances which have cytotoxic activities (165-175).
These include Paf-Acether (166), ammonium (167) and other 
substances including proteins and enzymes (172-175). The 
in vitro exposure of tissue culture cells to a 
concentrated bacterial supernatant in the presence of urea 
(30 mmol/L) demonstrated vacuolisation of the cells 
(167). The addition of the urease inhibitor 
acetohydroxamic acid prevented the development of 
vacuolisation. Conversely the addition of ammonium to the 
suspension caused vacuolisation indicating that ammonium 
produced by the urease activity of the bacterium had a 
cytotoxic effect in vitro. Studies using a rat model have 
shown that ammonium can cause a decrease in gastric 
mucosal potential difference and gastric epithelial damage 
(180). It has been suggested that the production of
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ammonium by the bacterium's urease activity could result 
in back diffusion of hydrogen ions across the mucosal 
barrier and cause cellular damage in vivo (181).
A 120 kDa protein has been identified in broth 
culture supernatants which also has vacuolising cytotoxic 
activity (172). One other study has suggested that the 
antibody response of mucosal IgA to a similar 120 kDa 
protein produced by H pylori may be responsible for the 
differing susceptibility of individuals to the development 
of gastric pathology (174).
The production of these toxins and any resulting 
inflammatory response could be involved in the development 
of type B gastritis. The effects of these cytotoxic 
agents may not be essential for the development of 
duodenal ulcers unless the colonisation of areas of 
gastric metaplasia in the duodenum was the primary event 
in the development of duodenal ulcers.
Mucus acts as a barrier to the back diffusion of 
hydrogen ions and any weakening of this barrier could also 
lead to inflammation and ulceration. The structure, 
alignment and turnover of mucous filaments are altered 
once H pylori is present (10,11,27-31). The mucous layer 
becomes less viscous and may therefore become more 
permeable to the organism, and also to the diffusion of 
hydrogen ions. The proteases and mucinases which the 
organism secretes may cause the alterations in the 
structure of the mucus. The production of ammonium by
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the organism also alters mucus structure by changing the 
pH in the environment of the mucus and therefore causes a 
change in conformation of individual molecules of mucus 
thereby altering mucous strand alignment (27-31). The 
alteration of the mucous layer might contribute to the 
development of antral gastritis or duodenitis. It might 
not be essential for the development of duodenal ulcers 
unless the colonisation of areas of gastric metaplasia was 
the primary event in the development of duodenal ulcers.
It has been proposed that ammonium produced by the 
organism's abundant urease activity could create an 
alkaline microenvironment in the vicinity of the organism 
by the neutralisation of gastric acid (19,181-183). This 
hypothesis has developed from the observation that the 
organism does not survive in an acidic environment except 
when urea is present (118,183-185).
The production of ammonium by the bacterium creating 
an alkaline microenvironment over the surface of the 
antral mucosa might block the suppression of gastrin 
release which occurs with increasing acid secretion. It 
might prevent the acid sensitive G cells of the antral 
epithelium sensing a fall in antral pH due to acid 
production.
The production of ammonium by the bacterium's urease 
activity therefore has the potential to explain the 
development of duodenal ulcer disease if the production of 
an alkaline microenvironment at the gastric antral
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epithelial surface results in an increase in plasma 
gastrin concentration and gastric acidity.
An inappropriate hypergastrinaemia occurs in 
association with Helicobacter pylori infection (19-26).
It has also been demonstrated that eradication of 
infection of the antral mucosa with H pylori is associated 
with a fall in basal plasma gastrin concentration and meal 
stimulated gastrin response (19-26). The inappropriate 
hypergastrinaemia has also been shown to result in 
increased intragastric acidity following meals 
(21,24,26). This failure to switch off gastrin secretion 
which may result in increased acid production could 
explain the increased duodenal acidity observed in some 
patients (19). Increased acid production could also lead 
to the development of gastric metaplasia of the duodenum 
and duodenitis with or without colonisation by the 
organism and ultimately to duodenal ulcer disease.
There is evidence from dogs and rats that the uptake 
of biological amines by the gastric antral mucosa results 
in gastrin release by the antral G cells (186-189). 
Biological amines which cause gastrin release include the 
ammonium ion (186). Amines would be less likely to be 
protonated at near neutral or alkaline pH than at acidic 
pH and would therefore be more able to cross the mucosal 
barrier into cells. The creation of an alkaline 
microenvironment in the region of the gastric antral 
mucosa could therefore result in increased uptake of
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biological amines from digested foods or uptake of 
ammonium produced by urease activity. This could also 
explain the observed increase in gastrin concentrations in 
patients with duodenal ulcer disease.
An attempt has been made to relate an increase in 
gastric juice ammonium ion concentration to plasma gastrin 
concentration, in order to determine whether ammonium 
uptake by the antral mucosa is of importance in humans 
(190). A relationship between the concentrations was not 
found. This might indicate that ammonium uptake was not a 
significant cause of gastrin release in humans, but 
gastric juice ammonium concentrations may not accurately 
reflect the concentrations to which the gastric antrum is 
exposed during infection with H pylori. In addition to 
the possible effects of ammonium on gastrin release 
gastrin might also be released in response to inflammation 
of the antral mucosa which might also result from the 
cytotoxic and mucolytic effects of ammonium produced by 
the urease activity of H pylori. The urease enzyme 
activity of H pylori therefore has the potential to 
explain many of the abnormalities associated with the 
development of duodenal ulcer disease and may therefore be 
a key factor in the development of duodenal ulcers.
2.11 The urease enzyme of Helicobacter pylori
Although Helicobacter pylori has been shown to 
possess many enzymes including gamma glutamyl transferase
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activity, alkaline phosphatase activity, oxidase activity, 
catalase activity and glutamate dehydrogenase activity 
(55,191) the one characteristic biochemical feature of the 
organism is its abundant urease activity (55-57). The 
urease enzyme of this organism has the highest activity 
of all bacterial ureases tested (192). The amount of 
ammonium produced in one study was 36 _+ 28 umol/min/mg of 
protein compared with 14.6 +_ 11.8 umol/min/mg protein for 
Proteus mirabilis, 5.5 + 4.9 umol/min/mg protein for 
Proteus vulgaris, 5.2 + 2.6 umol/min/mg protein for 
Morganella morganii and 4.6 +_ 1.4 umol/min/mg protein for 
Providenci rettgeri (193).
When the bacterium colonises the gastric mucosa its 
abundant urease activity has been reported to increase the 
gastric juice ammonium concentration and reduce the 
gastric juice urea concentration (182). Other 
investigators have not found any difference in urea 
concentrations between subjects with the infection and 
those without the infection (194,195).
It has been suggested that during initial infection 
with the organism its urease activity could result in the 
production of sufficient ammonium to effectively 
neutralise the gastric juice pH and cause achlorhydria 
(182). This may be of importance during acquisition of 
this infection as a number of studies have also 
demonstrated that the presence of urea is essential for 
the survival of the organism at low pH (118,183-185). In 
the absence of urea the organism does not survive at a pH
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of less than 4.0. These observations have resulted in the 
suggestion that the organism's urease activity creates an 
alkaline microenvironment to protect it from gastric 
acidity which is a potent bacteriocidal agent (185) (Fig 
2.1). It has also been suggested that H pylori may 
secrete urease activity in order to better mop up urea in 
its immediate vicinity and thereby better create an 
alkaline microenvironment (181). There is some 
experimental evidence to indicate that the organism may 
indeed excrete the enzyme in vitro as culture supernatants 
may contain urease activity (167). Partially purified 
urease enzyme for H pylori has a pH optimum of 8.7 which 
would indicate that the enzyme would not function if it 
was secreted into gastric juice as the low pH would 
inactivate it (193). When the organism colonises the 
gastric mucous layer it is found in close proximity to the 
epithelial cells below this. The gastric mucous layer 
acts as a barrier to the back diffusion of H* ions and 
as a result the pH below the mucus close to the epithelial 
cells may be closer to 6.0-7.0 pH units (196). This pH 
would be more favourable for the growth of the organism 
than that of gastric juice, but it still may not be 
optimal for its urease activity.
The Km for H pylori1s urease enzyme has been found to 
be in the range 0.2 - 0.7mmol/L (193,197). This is 
considerably lower than other microbial and plant ureases 
(192). This probably is due to adaptation of the enzyme 
for the concentrations of urea normally found in gastric 
juice, which tend to be two thirds of serum urea
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Fig. 2.1
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2H+ + 2CL’ Hydrochloric Acid
t
+ 2CL‘ Ammonium Chloride
The creation of an alkaline microenvironment using 
Helicobacter pylori urease enzyme activity.
concentrations. In contrast urease enzymes of proteus 
species are adapted for the hydrolysis of urea at 
concentrations of 400-500 mmol/L found in urine (192).
Even with a low Km it is unlikely that H pylori urease 
activity would ever operate at maximum velocity at normal 
gastric juice urea concentrations.
In other bacteria urease enzyme activity is used to 
scavenge ammonium from urea (198). Once ammonium has been 
generated by the hydrolysis of urea it will be taken up by 
the cell and enter the metabolic pathways of the organism 
by one of two main routes (Fig 2.2). Glutamate 
dehydrogenase activity may be used to catalyse the 
conversion of alpha ketoglutarate and ammonium into 
glutamate (199). Glutamine synthetase may also be used. 
This enzyme converts glutamate and ammonium into glutamine 
which may be used as a labile intracellular pool of 
metabolically available amino groups (200). H pylori 
possesses glutamate dehydrogenase activity which would 
allow it to use urease activity as a method of scavenging 
nitrogen (55). Even if this is the function of the urease 
activity the reason it contains such abundant enzyme 
activity remains unclear.
Most bacterial ureases are considered to be 
intracellular enzymes although some have been localised in 
association with the cell's periplasmic membrane (192). 
Localisation of H pylori urease activity by means of 
urease linked precipitation of silver followed by 
visualisation of the precipitate by electron microscopy
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Helicobacter pylori.
has suggested that the urease activity of this organism 
was associated with its periplasmic membrane (201). 
Investigation of the location of the urease by using 
monoclonal antibodies has also demonstrated localisation 
of this enzyme on the extracellular surface of the 
organism (202). Similar work with proteus species has 
also suggested localisation of urease activity in the 
periplasm and outer membrane of this species (203).
The urease activity of H pylori is expressed 
constitutively but can also be further induced if the 
organism is grown in a medium which contains urea (191). 
The mechanism by which the organism's urease activity is 
controlled is currently unknown. Product inhibition by 
ammonium does not inhibit urease activity (193). Whether 
glutamine or glutamate inhibit the enzyme, or are involved 
in its control, is unknown (191,193). Similarly, the role 
of amino acids in the control of this enzyme has not been 
defined, although the metabolism of these may also produce 
ammonium.
There are two possible roles for the organism's 
urease activity. It may be used to create an alkaline 
microenvironment which could explain the increased gastrin 
concentrations in patients with the infection. An 
alkaline microenvironment could also explain the survival 
of the organism in the gastric acid. The enzyme could 
also be used to scavenge nitrogen from urea. An alkaline 
microenvironment would not need to be created and the 
raised concentrations of gastric juice ammonium would
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therefore only represent urea nitrogen surplus to the 
organism's needs produced as a result of uncontrolled 
urease activity. Investigation of the function of the 
organism's urease activity may help explain its survival 
in the potentially hostile gastric environment and the 
development of raised gastrin concentrations which occur 
in association with infection of the antral mucosa with 
H pylori. The possibility of a new therapeutic approach 
to the treatment of duodenal ulcers might also exist as 
the organism is sensitive to low pH in the absence of the 
protective effect of urease activity.
2.12 Treatment of Infection with Helicobacter pylori
Of the treatments currently available for duodenal 
ulcers only the use of tripotassium dicitrato bismuthate 
(DeNol) (Gist Brocades, Surrey, UK) as part of triple 
therapy with metronidazole and amoxycillin may result in 
prolonged healing of a duodenal ulcer and also in 
eradication of Helicobacter pylori (144-146). Treatment 
with Hz receptor antagonists such as ranitidine (Glaxo, 
Glaxo Laboratories, Middlesex, UK) and cimetidine (Smith, 
Kline and French Laboratories, Welwyn Garden City, UK) and 
newer agents such as the proton pump inhibitor omeprazole 
(Astra Pharmaceuticals, Herts, UK) result in a decrease in 
gastric acid output and also lead to healing of the 
ulcer. Treatment with H2 receptor antagonists does not 
eradicate H pylori. Failure to eradicate the organism is 
associated with recurrence of the ulcer once treatment has
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stopped. Up to 80% of individuals treated with an H 2 
receptor antagonist in one study relapsed within a year of 
stopping treatment (144). As a result maintenance 
treatment with H2 receptor antagonists is necessary and 
adds to the cost of the treatment.
The proton pump inhibitor omeprazole (Astra 
Pharmaceuticals, Herts, UK) is also effective in healing 
duodenal ulcers. There is some evidence that treatment 
with this agent might reduce H pylori infection 
(204-207). Unfortunately many of these studies only 
tested for eradication of the organism on completion of 
treatment and not one month after cessation of treatment. 
There is no evidence of in vitro activity against H pylori 
(208). One study which did look for evidence of 
eradication of H pylori one month after treatment with 
omeprazole showed no activity against H pylori (209). It 
was suggested that the previous reports of eradication 
could have been due to bacterial overgrowth in the stomach 
as a result of raised gastric juice pH.
Omeprazole (Astra Pharmaceuticals, Herts, UK) is 
activated in an acidic environment and once activated 
combines covalently with sulphydryl groups to inactivate 
the H V K "  ATPase of the gastric epithelial cells 
(210). The virtually complete stoppage of gastric acid 
production by omeprazole results in raised plasma gastrin 
concentrations. There is concern that these high plasma 
concentrations of gastrin could promote the development of 
gastrointestinal neoplasia and prolonged treatment of
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duodenal ulcers with omeprazole (Astra Pharmaceuticals, 
Herts, UK) is not recommended (210). Tripotassium 
dicitrato bismuthate (DeNol) (Gist, Brocades, Surrey, UK) 
both heals duodenal ulcers and eliminates H pylori in some 
individuals. The mechanism by which ulcer healing occurs 
when this is used is not known. It is suggested that 
DeNol creates a barrier to the back diffusion of hydrogen 
ions thereby promoting the healing of ulcers (211-214).
It also eradicates H pylori (144-146). This may be due to 
the known toxic effects of heavy metals (215,216).
Although the eradication of H pylori results in prolonged 
remission from duodenal ulcer disease it is not essential 
for the healing of duodenal ulcers with bismuth 
preparations as the organism is not eradicated in some 
individuals treated with bismuth preparations (217). 
Thereby demonstrating that healing can occur despite 
continued colonisation with the organism.
Eradication of H pylori in up to 90-95% of subjects 
can be achieved by the combination of DeNol with 
amoxycillin and metronidazole, with treatment extended 
over a minimum of a 2 week period (144,146,218). The 
extensive use of this triple therapy in all patients with 
duodenal ulcers could result in the spread of antibiotic 
resistance among H pylori. There is already some evidence 
that this is occurring (219). This restricts the use of 
triple therapy for patients with persistent or complicated 
ulcer disease.
A new treatment which would help eradicate the 
organism but avoid the risk of antibiotic resistance would
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allow the full potential benefits of treatment of H pylori 
infection to be achieved. Potential benefits from 
eradication of the organism would include cessation of 
lifelong treatment for ulcer disease, and a reduction in 
the incidence of gastric carcinoma and treatment of 
H pylori related disease in children.
2.13 Overall summary
While Helicobacter pylori may not be the sole cause 
of the development of duodenal ulcers there is clear 
evidence that infection of the gastric antral mucosa by 
the organism, is one of the most important acquired 
factors in the development of duodenal ulcers (218). In 
addition, persistence of infection of the antral mucosa 
following the healing of a duodenal ulcer almost 
inevitably results in the relapse of the duodenal ulcer 
(144-146, 217).
The eradication of the organism has been associated 
with a reduction in fasting gastrin concentration, meal 
stimulated gastrin release and acid output (19-26). This 
increase in gastrin concentration may be the link between 
the infection and the development of duodenal ulcer 
disease.
When antral infection is present the urease activity 
of this organism may cause increased gastric juice 
ammonium concentrations. Reduced gastric juice urea 
concentrations have been reported (182), but other 
investigators have found no difference in urea
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concentrations between subjects with the infection and 
those without the infection (194,195).
The reason the organism possesses abundant urease 
activity is not known. It has been suggested that because 
H pylori's urease activity has a protective effect at low 
pH that possession of this enzyme may enable the organism 
to survive in the acid gastric environment through the 
neutralisation of gastric acidity (183-185).
Ammonium produced by urease activity might be used to 
maintain a favourable extracellular pH by creating an 
alkaline microenvironment close to the antral mucosal 
surface where the gastrin producing (G cells) are 
located. The production of ammonium with an increase in 
the local pH at this site could result in inappropriate 
gastrin release leading to the observed increased meal 
stimulated gastrin response and gastric acidity. If the 
urease activity was used to alter the pH of the 
extracellular environment of the organism then large 
amounts of extracellular ammonium would be produced. The 
pH of the environment close to the antral mucosal surface 
may be closer to neutrality than that of the gastric 
juice. If this is the case then H pylori may not need to 
possess urease activity to maintain a favourable 
extracellular pH. The organism might therefore possess 
urease activity to scavenge nitrogen from urea which 
diffuses from the bloodstream into the gastric juice. 
Cellular uptake of ammonium produced by urease activity 
would therefore be expected.
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To distinguish between these possibilities and to 
clarify the biochemical effects of infection of the 
gastric antral mucosa with H pylori a series of studies 
were undertaken.
The effect of the organism's urease activity on 
gastric juice ammonium and urea concentrations in 
individuals with normal and increased plasma urea 
concentrations was studied. A relationship between 
gastric juice ammonium and urea concentrations and the 
presence of infection was sought.
The effect of stimulating and inhibiting the 
organism's urease activity on plasma gastrin concentration 
and meal stimulated gastrin response was investigated.
The effect of increasing intragastric pH by the infusion 
of a buffer solution on basal plasma gastrin concentration 
and meal stimulated gastrin response in infected and 
non-infected subjects was also investigated.
In vitro experiments were also undertaken to 
investigate alteration in urease activity with pH, the 
effect of urease activity on survival of the organism in 
different pH environments, and uptake of ammonium produced 
from hydrolysis of urea.
These studies were conducted to establish whether the 
raised plasma gastrin concentrations found in individuals 
with duodenal ulcers resulted from urease activity 
creating an in vivo alkaline microenvironment and if the 
effect of the organism's urease activity on in vitro 
survival in hostile conditions was also due to the 
production of an alkaline environment.
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CHAPTER 3
MATERIALS AND ANALYTICAL METHODS
MATERIALS AND ANALYTICAL METHODS
3.1 Detection of Helicobacter pylori infection
3.2 Culture of Helicobacter pylori
The method of Miles and Misra was used to establish 
survival of the organism in the samples (220). Viable 
colony counts were obtained on blood agar plates after 3 
days of incubation at 37°C in a microaerophilic 
atmosphere (BBL CampyPak Gas Generating System). In the 
in vitro studies the survival of the organism was 
expressed as a percentage of the starting inoculum 
calculated from the dilution of the viable colony count in 
the initial broth suspension.
3.3 Histological Examination of Antral Biopsies 
Antral biopsies were stained using the haematoxylin
and eosin stain. They were examined double blind by a 
single pathologist. An aggregate gastritis score of 
between 1 and 10 was determined on biopsy samples by the 
method described by Rauws (125).
3. 4 14C-Urea Breath Test
14C-Urea breath tests were performed in the 
Department of Nuclear Medicine at the Western Infirmary in 
Glasgow. Following a 14-hour overnight fast the patient 
drank 240 ml Ensure Plus (Abbott, Maidenhead, UK) to delay 
gastric emptying. This was followed by 0.4 MBq 14C-urea
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in 20 ml water. Samples of breath carbon dioxide were 
then collected every 10 minutes for 30 minutes prior to 
administration of the isotope and for a further 120 
minutes following it. Breath carbon dioxide was trapped 
by asking the patient to exhale through a tube of 
anhydrous calcium chloride into a vial containing 2 mmol 
of hyamine in 2 ml of ethanol. Phenolphthalein was added 
as an indicator and became colourless when 1 mmol of 
exhaled C02 had been trapped. The appearance of 14C 
labelled C02 in the breath samples was followed by 
liquid scintillation counting of the trapped labelled 
COz following the addition of 10 ml of scintillant to 
the vial. The area under the curve of the breath test was 
calculated using the trapezoid rule for the time periods 
0-30 min, 0-40 min, 0-60 min and 0-120 minutes of the 
test.
3.5 Measurement of urea concentration in gastric juice 
and buffer solutions
Several methods for the measurement of urea in 
gastric juice samples and in buffer samples collected 
during in vitro experiments were used:
A) Chemical methods of urea analysis.
1) o-Pthalaldehyde method:
Urea was analysed in gastric juice and buffer 
samples collected during the in vitro experiments 
by the ortho-pthalaldehyde method using an 
American Monitor Perspective Analyser or an 
American Monitor Excel Analyser (American 
Monitor, West Sussex, UK) (221). When
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appropriate samples were diluted 1 in 3 with 0.2 
mol/L phosphate buffer pH 7.40 prior to analysis.
2) Diacetylmonoxime method: Urea was also measured 
in gastric juice samples using the 
diacetylmonoxime method (222). Reagents were 
purchased from the Sigma Chemical Company 
(Dorset, UK). No dilution of the gastric juice 
sample was required. 10 ul of sample was added 
directly to 5 ml of working diacetylmonoxime 
reagent, incubated for 10 min in a boiling water 
bath, cooled for 5 minutes in tap water and the 
absorbances were read at 575 nm using a SP8-200 
UV/VIS scanning spectrophotometer (Pye Unicam,
UK) .
B) Enzymatic methods of urea analysis
1) Automated Urease methods
i ) Cobas Bio Analyser
Urea was measured by following the decrease in 
absorbance at 340 nm due to the consumption of 
NADH by linked urease and glutamate dehydrogenase 
enzymatic reactions (Fig 3.1). Ammonia produced 
by the hydrolysis of urea was used to convert 
alpha ketoglutarate to glutamate by glutamate 
dehydrogenase with the consumption of NADH 
(223). Reagents were purchased from the Sigma 
Chemical Company (Dorset, UK) and the method 
automated using the Cobas Bio centrifugal
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Fig. 3.1
jp  Urease
h 2n -c -n h 2 + H20   ► C02 + 2NH3
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dehydrogenase ^ ^ 2
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a ketoglutaric acid glutamic acid
The enzymatic measurement of urea. The concentration of urea is 
proportional to the rate of utilisation of NADH. This is followed by 
the decrease in absorbance at 340nm as NADH is consumed.
analyser (Roche, Welwyn Garden City, UK) 
following a protocol supplied by the Sigma 
Chemical Company (Dorset, UK) (Table 3.1). 
ii) Continuous Flow Analysis
Samples of gastric juice from the in vivo 
infusion experiment were analysed for urea 
concentration using a modification of the urease 
method on a Technicon SMAC (Technicon, 
Basingstoke, UK). A blank channel in addition to 
the test channel was also used. Samples were 
diluted where appropriate using a 9 g/L saline 
solution.
2) Urease method linked to the Berthelot reaction
A urease method linked to the Berthelot reaction 
which detected the ammonia produced as a result of 
the hydrolysis of urea in the sample was also used 
(Fig 3.2) (224). Reagents were purchased from the 
Sigma Chemical Company (Sigma, Dorset, UK). Samples 
were diluted 1/10 in 0.2 mol/L phosphate buffer pH
7.4 prior to analysis. The urease reagent supplied 
was reconstituted using deionised water or 0.2 mol/L 
phosphate buffer pH 7.4. Samples (0.1 ml) were 
incubated for 30 minutes at room temperature with 0.5 
ml of urease reagent in order to hydrolyse all urea 
present. Following addition of 3 ml of the acid 
reagent and 2 ml of the phenol reagent the samples 
were incubated at room temperature for 30 minutes to
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Table 3.1
Units 3
Calculation Factor 0
Standard 1 1.75
Standard 2 3.45
Standard 3 15. 7
Limit 25.0
Temperature (°C) 30
Type of Analysis 4
Wavelength (nm) 340
Sample Volume (ul) 3
Diluent Volume (ul) 30
Reagent Volume (ul) 250
Incubation time 0
Second reagent 0
Time of 1st Reading 20
Time interval 20
Number of readings 2
Blanking mode 1
Printout mode 2
Instrument settings used with the enzymatic urease
method for measuring urea installed on a Cobas Bio
centrifugal analyser (Roche, Welwyn Garden City, UK).
Fig. 3.2
?  Urease
H^N - C - NH2 + H20 --------------------- > C02 + 2NH3
Nitroprusside
>0NH3 + OCi- + 2 ( '  \>- O H ---------- ------  =( )= o
+
Indophenol blue
The Berthelot reaction for the measurement of urea.
The concentration of urea is proportional to the amount of indophenol 
blue produced. Indophenol blue may be measured by its absorbance at 
575nm.
allow the colour to develop. The concentration of 
urea was proportional to the absorbance at 575 nm. A 
blank for each sample was also analysed.
3.6 Measurement of Ammonium Concentration in gastric 
juice and buffer solutions
The ammonium concentration in these samples was 
measured by an enzymatic method (Sigma Chemical Company 
Ltd., Dorset, UK) (225). The detection of ammonium ions 
was followed by the consumption of NADH during conversion 
of alpha ketoglutarate and ammonium ions to glutamate by 
glutamate dehydrogenase. The samples from both in vivo 
and in vitro experiments were diluted with 0.2 mol/L 
phosphate buffer pH 7.40 to bring the concentration of 
ammonium into the linear range of the method (30-1000 
umol/L). The analysis of ammonium ions in these samples 
was automated using a Cobas Bio Centrifugal Analyser 
(Roche, Welwyn Garden City, UK). The program used to 
operate the instrument was supplied by Sigma Chemical Co 
(Dorset, UK) (Table 3.2).
In the in vitro experiments the percentage recovery 
of ammonium was calculated assuming that the urea lost 
from the solution had been completely hydrolysed. The 
final urea concentration in the buffer was subtracted from 
the initial urea concentration and the result multiplied 
by 2 to give the expected final ammonia concentration.
The measured concentration of ammonium could then be
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Table 3.2
Units 12
Calculation Factor 0
Standard 1 5
Standard 2 5
Standard 3 0
Limit 20
Temperature 30
Type of Analysis 6
Wavelength 340
Sample Volume (ul) 40
Diluent Volume (ul) 20
Reagent Volume (ul) 260
Incubation time 300
Start Reagent Volume (ul) 20
Time of first reading 10.0
Time interval 300
Number of readings 2
Blanking mode 1
Printout mode 1
Instrument settings used with the ammonia method
installed on a Cobas Bio Centrifugal analyser
(Roche, Welwyn Garden City, UK).
expressed as the percentage of the expected final ammonium 
concentration calculated from the fall in urea 
concentration to give percentage recovery of ammonia.
3.7 Measurement of Urease activity
A kinetic spectrophotometric assay was developed for 
the measurement of urease activity in samples from in 
vitro studies. The urease activity in samples was 
measured by following the consumption of ammonia produced 
as a result of urease activity by a linked glutamate 
dehydrogenase reaction (Fig 3.3). Glutamate dehydrogenase 
uses NADH in the production of glutamate from ammonia and 
alpha ketoglutarate. The rate of ammonia production was 
therefore followed by the consumption of NADH which was 
measured by the change in absorption of the incubate at 
340 nm. The concentrations of the reagents were arranged 
so that the utilisation of NADH would be directly 
proportional to urease activity in the sample. Samples 
containing urease activity were incubated with excess 
glutamate dehydrogenase, alpha ketoglutarate and NADH. A
2.5 mol/L urea solution was used as the start reagent. A 
pre-incubation period of 3 min prior to the addition of 
the urea start reagent was used to eliminate any 
endogenous ammonia. Jackbean Urease (EC 3.5.1.5) supplied 
by Sigma was used as a standard (Sigma Chemical Company, 
Dorset, UK). The urease assay was linear up to a 
concentration of 500 IU/L. The instrument settings used 
are listed in Table 3.3.
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Fig. 3.3
Urea + Urease activity---------------------- > C02 + NH3
Glutamate
NADH + NH3 + a ketoglutarate  > NAD+ + glutamate + H20
Dehydrogenase
The urease activity in the sample is measured by the rate of 
utilisation of NADH in the linked glutamate dehydrogenase 
reaction.
Table 3.3
Units 10
Calculation Factor 1
Standard 1 0
Standard 2 0
Standard 3 0
Limit 0
Temperature 37
Type of Analysis 3
Wavelength 340
Sample Volume (ul) 2
Diluent Volume (ul) 20
Reagent Volume (ul) 280
Incubation time 120
Start Reagent Volume (ul) 50 
Time of first reading 10.5
Time interval 10
Number of readings 18
Blanking mode 1
Printout mode 3
Instrument settings used with the urease assay
installed on a Cobas Bio Centrifugal analyser
(Roche, Welwyn Garden City, UK).
3.8 Measurement of Gastrin concentration
Blood samples for gastrin determination were 
collected in lithium heparin tubes containing 100 klU of 
trasolol. Following centrifugation at 3,000 g for 10 min 
in a refrigerated centrifuge at 4°C the plasma was 
stored at -20oC until analysis. Plasma gastrin was 
initially measured at Queens University Belfast, by a 
radioimmunoassay using antibody R98 which has a lower 
limit of detection of 5-10 ng/L (226). Plasma gastrin 
concentrations in subsequent studies were measured using a 
commercially available radioimmunoassay (CIS (UK) Ltd., 
Buckinghamshire, UK). This gastrin assay reacted 100% 
with gastrin 17 and 72% with gastrin 34. The minimum 
detection limit of the assay was 20 ng/L. The inter-assay 
coefficient of variation was less than 10% from 40-700 
ng/L. All samples for each patient were measured with the 
same assay. All samples from each experiment were 
measured in the same batch.
3.9 Manufacture of Buffer solutions and other solutions 
for in vivo experiments
1) Dextrose solution for intragastric infusion:
The pH of 500 ml of 5% Dextrose solution for 
intravenous infusion (Baxter, Surrey, UK) was 
adjusted to 1.80 by the addition of 1 ml of 
concentrated hydrochloric acid. To add urea, 
when required, to this solution, 1.5 g of sterile 
urea powder was dissolved in 30 ml of the
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dextrose solution aspirated aseptically from the 
sealed 500 ml intravenous solution bag and when 
dissolved was reinjected into the bag.
2) 0.2 mol/L Citrate Buffer pH 7.0.
100 ml of fresh 2 mol/L citric acid solution was
added to 315 ml of fresh 2 mol/L sodium hydroxide 
solution in a 1L volumetric flask. Water was 
added up to the 1L mark and mixed. The buffer 
was then sealed in 500 ml glass bottles with a 
top containing a self-sealing rubber septum. The 
solution was sterilised by heating. It was 
stored in the dark at room temperature until 
use.
3.10 Manufacture of Buffer and other solutions for in
vitro experiments
1) A series of 0.2 mol/L citrate buffers with a pH
ranging from 2.0 to 7.0 were made using stock
solutions of 2 mol/L citric acid and 2 mol/L 
sodium hydroxide.
To 100 ml of fresh stock 2 mol/L citric acid the 
amounts of 2 mol/L sodium hydroxide listed in 
Table 3.4 were added and the final volume of the 
solution was made to 1L with distilled water.
To make a 0.2 mol/L citrate buffer pH 1.5 10 ml 
of concentrated hydrochloric acid was added to 
100 ml stock 2 mol/L citric acid and the volume 
of the solution was made to 1L with distilled 
water.
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Table 3.4
0.2 mol/L citrate buffer solutions 
Required pH Volume of 2 molar NaOH
(ml)
2.0 0
3.0 60
4.0 130
5.0 210
6.0 280
7.0 315
The volume of 2 mol/L NaOH to be added to 100 ml 2 mol/L 
citric acid solution to produce 1L buffer with the required 
pH. The final volume is made up to 1L with distilled water.
In experiments comparing 0.2 mol/L citrate buffer 
pH 3.0 with 0.2 mol/L citrate buffer pH 6.0, the 
osmolality of the pH 3 buffer was adjusted to be 
the same as that of the pH 6.0 buffer by adding 
0.641 g sodium chloride per 100 ml pH 3.0 
buffer. Isomolar saline solution used in the 
experiments was 0.25 mol/L sodium chloride 
solution. The pH of this solution prior to use 
was adjusted if necessary to 6.0.
2) 0.2 mol/L Isocitrate Buffer
The trisodium salt of isocitric acid was obtained 
from the Sigma Chemical Company (Poole, Dorset). 
To make a 0.2 mol/L solution pH 6.0, 12.68 g of 
powder was dissolved in 250 ml of deionised 
water. The pH was adjusted to 6.0 by the 
addition of 1 mol/L hydrochloric acid.
3) 0.2 mol/L Sodium Acetate Buffer
To make 1L 27.2 g sodium acetate (trihydrate) was 
dissolved in 1L of water and the pH adjusted to
6.0 with glacial acetic acid. The osmolality was 
adjusted to that of 0.2 mol/L citrate buffer with 
NaCl solution.
4) 0.2 mol/L Phosphate Buffer
To make 1L 13.68 g of sodium dihydrogen phosphate 
and 1.75 g of disodium hydrogen phosphate were 
dissolved in deionised water. The pH was 
adjusted to 6.0 if necessary and the volume made
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to 1L. The osmolality was adjusted to that of 
0.2 mol/L citrate buffer with NaCl solution.
3.11 Collection of Fasting Gastric Juice Samples
During endoscopy and just after emptying the stomach 
2 ml of gastric juice was aspirated through the suction 
channel of the endoscope and collected in a trap inserted 
in the suction line. Samples were sealed in 2 ml tubes 
and frozen at -20°C until analysis. On thawing samples 
were centrifuged at 3000 g for 10 min to remove the 
mucous.
3.12 Chemicals
All reagents and chemicals were of analar grade and 
were supplied by BDH (Thornliebank, Glasgow) except where 
otherwise stated.
3.13 Statistical Methods
Non-parametric statistical methods were used for the 
analysis of the data. The Sign Rank Wilcoxon test was 
used for paired data and for non-paired data the Mann 
Whitney U test was used.
3.14 Ethical Permission
All studies involving patients received the approval 
of the Western Infirmary Ethical Committee, and each 
patient gave written informed consent.
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CHAPTER 4
THE MEASUREMENT OF UREA AND 
AMMONIUM CONCENTRATIONS 
IN GASTRIC JUICE
THE MEASUREMENT OF UREA AND AMMONIUM CONCENTRATIONS
IN GASTRIC JUICE
4.1 Introduction
There is disagreement concerning the concentrations 
of urea and ammonium in gastric juice samples from 
subjects with Helicobacter pylori infection. Marshall and 
colleagues reported mean urea concentrations of 0.45 
mmol/L in individuals with the organism compared with 2.9 
mmol/L in individuals who were not infected (182). Mean 
urea concentrations of 3.27 mmol/L and 4.8 mmol/L for 
H pylori positive individuals and 3.4 and 4.3 mmol/L for 
H pylori negative individuals have also been reported by 
other groups (194,195).
There is also disagreement concerning the 
concentrations of ammonium ions in gastric juice.
Marshall and colleagues found mean ammonium concentrations 
of 34 mmol/L in infected subjects and 11.5 mmol/L in 
non-infected subjects (182). The difference in ammonium 
concentrations between infected and non-infected subjects 
was considered to be a poor indicator of the presence of 
infection (182). Kim and colleagues reported mean 
ammonium concentrations of 5.48 mmol/L in samples from 
infected subjects and mean concentrations of 1.26 mmol/L 
in non-infected subjects (196). In this study raised 
gastric juice ammonium concentrations were considered to
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be a useful indicator of the presence of infection with a 
predictive value of 78.3% if a threshold of 3 mmol/L was 
exceeded.
In none of these studies were the methods of 
measuring urea and ammonium concentrations clearly 
described (182,195,196).
Several different methods may be used for the 
measurement of urea and ammonium concentrations in 
biological samples (221-225). There are also well 
recognised potential interferences in the measurement of 
urea and ammonium in biological samples. Interference in 
the measurement of urea may occur as a result of the 
measurement of ammonia present in samples when urease 
linked methods such as the berthelot reaction (Fig 4.1) or 
other urease methods are used (Fig 4.2). The low pH of 
gastric juice samples could also interfere in the 
enzymatic methods of measurement of urea by inhibiting the 
urease enzyme. Differences between the matrix of serum 
and gastric juice samples such as a lower protein 
concentration, or lower gastric juice pH, the presence of 
mucous or high bile acid concentrations might interfere in 
both urease and chemical methods of urea measurement.
Ammonia concentrations may be difficult to measure 
accurately as a result of contamination of samples with 
ammonia from the laboratory environment as methods for the 
measurement of ammonium are able to detect micromolar 
concentrations of ammonium. The activity of urease,
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Fig. 4.1
O
Urease
H2N - C - NH2 + H20 ......... > C02 + 2NH3
r\NH. + OCi' + 2 ( ' O H ---------- > O O+
Indophenol blue
Nitroprusside 
  
The Berthelot reaction for the measurement of urea.
The concentration of urea is proportional to the amount of indophenol 
blue produced. Indophenol blue may be measured by its absorbance at 
575nm.
Fig. 4.2
O Urease
i
-  C -  NH2 + H20 ...........................> C02 + 2NH3
Glutamate
NADH + NH3 + a ketoglutarate   > NAD+ + glutamic acid
dehydrogenase
The enzymatic measurement of urea. The concentration of urea is 
proportional to the rate of utilisation of NADH. This is followed by 
the decrease in absorbance at 340nm as NADH is consumed.
protease or transaminase enzymes in samples could also 
lead to falsely high measured concentrations of ammonia. 
The low pH of gastric juice samples might also interfere 
with the activity of glutamate dehydrogenase used in the 
enzymatic measurement of ammonia (Fig 4.3).
The use of different methods of measuring urea and 
ammonium concentrations in gastric juice might have 
resulted in the different concentrations of urea and 
ammonium reported in gastric juice samples. An assessment 
of methods of measuring these analytes in gastric juice 
samples was therefore conducted.
4.2 Methods
Following the passage of a nasogastric tube and 
pentagastrin stimulation gastric juice was collected from 
one healthy volunteer who had H pylori infection. The 
gastric juice samples were stored at -20°C until 
analysis.
The effects of pH and gastric juice ammonium 
concentration on the imprecision, inaccuracy and detection 
limit of 4 methods of urea analysis were investigated.
The methods investigated were a rate reaction enzymatic 
method automated on the Cobas Bio (Roche, Welwyn Garden 
City, UK), the o-phthalaldehyde method automated on the 
Excel analyser (American Monitor, West Sussex, UK), a 
manual diacetylmonoxime method (Sigma Chemical Company, 
Dorset, UK) and a manual urease method linked to
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Glutamate
NADH + NH3 + a ketoglutarate--------------------
dehydrogenase
Fig. 4.3
> NAD+ + glutamic acid
The measurement of ammonia. The concentration of ammonia is 
proportional to the rate of utilisation of NADH. This is followed by 
the reduction in absorbance of the solution at 340nm
the berthelot reaction (Sigma Chemical Company, Dorset, 
UK). The effect of pH on the inaccuracy and imprecision 
of the enzymatic ammonia method automated on the Cobas Bio 
(Roche, Welwyn Garden City, UK) (Sigma Chemical Company, 
Dorset, UK) was also investigated.
1) The effect of pH on the measured gastric juice urea
concentration
This was examined by taking portions of the gastric 
juice and adjusting the pH of the juice by the addition of 
small amounts of 2 mol/L sodium hydroxide solution or 1 
mol/L hydrochloric acid. The pH of the gastric juice was 
measured using a Corning 220 pH meter (Corning, Herts,
UK). Once the basal pH of the gastric juice had been 
measured 75 ul of 2 mol/L sodium hydroxide was added to 
increase the pH to 4.0, a portion of pH 4.0 gastric juice 
was set aside and the pH of the remainder was again 
increased to pH 6.5 by the addition of more sodium 
hydroxide solution. Again a portion of the gastric juice 
was set aside. The pH of the remaining gastric juice was 
then titrated back to the original value by the addition 
of approximately 50 ul of 1 mol/L hydrochloric acid. 
Portions (0.9 ml) of the four pH adjusted gastric juice 
samples then had 0.1 ml of stock 5 mol/L urea solution or 
deionised ammonia free water added to produce gastric 
juice samples with a low urea concentration, or 5 mmol/L 
urea.
The inaccuracy of the measurement of urea in gastric 
juice samples with a low pH was assessed by calculating
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the recovery of added urea in portions of gastric juice to 
which urea had been added to give concentrations of 2.5,
5, 10 and 20 mmol/L. The samples were assayed by each 
method in triplicate.
2) The effect of ammonium chloride on measured urea 
concentration
Gastric juice samples had 0.1 ml of 100 mmol/L 
solution of ammonium chloride added to increase the total 
ammonium concentration by 10 mmol/L. These samples 
containing ammonia were split into 2 portions and stock 
urea solution added to give a final urea concentration of 
5 mmol/L in one portion. The concentrations of urea were 
then measured in each of the portions of gastric juice by 
all four methods.
3) The detection limit of urea analysis
Samples of gastric juice were spiked with stock urea 
solution to give a final urea concentration of 5 mmol/L. 
The gastric juice was then diluted, 1/2, 1/5, 1/10, 1/20 
to give a range of urea concentrations from undetectable 
to 5 mmol/L. The urea concentrations in these dilutions 
were measured by all four methods.
4) The effect of pH on the measured gastric juice 
ammonium concentration
Samples of gastric juice had their pH adjusted as 
described for urea. Portions of 100 mmol/L ammonium 
chloride solution were then added to produce 5 mmol/L and 
10 mmol/L ammonia concentrations. Samples were then 
analysed in quintuplicate for ammonium concentration using
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the Sigma method adapted for the Cobas Bio centrifugal 
analyser.
The inaccuracy of the ammonia method was assessed by 
measuring the recovery of ammonium chloride which was 
added to portions of gastric juice to give final 
concentrations of 2.5, 5, 7.5 and 10 mmol/L. Basal 
gastric juice samples collected from several other 
subjects who had H pylori infection were also analysed in 
replicate to assess the imprecision of measurement using 
native gastric juice.
5) The stability of gastric juice ammonium concentration 
on storage
Samples were stored in a freezer at -20°C over a 3 
week period and repeatedly re-analysed.
4.3 Results
1) The effect of pH on urea measurement
Alteration of the pH of the samples did not markedly 
interfere in any of the 4 urea methods investigated (Table 
4.1 and Table 4.2). Measured urea concentrations compared 
well with the expected concentrations with all the methods 
except the berthelot linked urease method (Table 4.2).
The use of 0.2 mol/L phosphate buffer as a diluent for the 
urease enzyme used in the berthelot method did not 
increase the urea concentration obtained by this method. 
The enzymatic urease method needed to be blanked as the 
measured basal gastric juice urea concentrations were
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Table 4.1
Mean Urea concentration in gastric juice
(mmol/L)
pH 1.56 pH 4.13 pH 6.49 pH 1.60
o-pthalaldehyde 0.3 0.2 0.2 0.2
method
Diacetylmonoxime 0.3 0.2 0.2 0.3
method
Urease method
unblanked 1.9 1.9 1.7 1.8
3erthelot linked
Urease method 0.3 0.2 0.2 0.1
The effect of gastric juice pH on the measurement of 
basal urea concentrations prior to the addition of 
urea to samples.
Table 4
o-pthalaldehyde
method
Diacetylmonoxime
method
Urease method 
unblanked 
(blanked)
Berthelot linked 
Urease method
pH 1.56
4.8 4.6
4.5 4.3
7.0 6.9
(5.2) (5.1)
4.3 3.0
pH 6.49 pH 1.60
4.6 4.9
4.3 4.9
6.9 6.6
(5.2) (4.8)
3.0 4.0
Mean Urea concentration in 
gastric juice 
mmol/L
pH 4.13
The effect of gastric juice pH on the measurement of 
urea concentrations after the addition of 5 mmol/urea.
higher with this method than in the other methods (Table 
4.1).
The percentage recovery of added urea is shown in 
Table 4.3. The recovery of urea was best with the blanked 
enzymatic urease method (97-105%) and with the 
o-pthalaldehyde method (92-98%).
The inter-assay coefficient of variation (CV) of 
analysis at each of the urea concentrations investigated 
demonstrated that the blanked urease enzymatic method and 
o-pthalaldehyde methods were least imprecise (Table 4.4). 
The bertholet reaction had unacceptable imprecision 
(20.4%-59.2%).
2) The effect of ammonium on the measurement of urea
The addition of ammonium chloride did not interfere
with the measurement of urea by either the diacetyl
monoxime method or the o-pthalaldehyde method (Table 
4.5). There was interference in the enzymatic urease 
method when it was not blanked. This method depends on 
the measurement of ammonia to determine urea 
concentration. If appropriate blanking was used then this 
was not a problem (Table 4.2).
3) The detection limit of urea analysis
The automated o-pthalaldehyde method had the lowest
detection limit (Table 4.6).
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Table 4.3
Percentage recovery of added urea
pH 1.56 pH 4.13 pH 6.49 pH 1.60
o-pthalaldehyde 96 92 92 98
method
Diacetylmonoxime 89 86 86 98
method
Urease method
(blanked) 104 101 105 97
Berthelot linked
Urease method 86 60 60 80
Recovery of 5 mmol/L urea added to portions of gastric 
juice.
Table 4.4
Coefficient of Variation
at a range of urea concentrations
2.5mmol/L 5mmol/L IQmmol/L 20mmol/L
o-p-thalaldehyde 5.4 5.0 4.6 3.9
method
Diacetylmonoxime 16.0 12.0 9.8 8.3
method
Urease method blanked 5.4 2.8 10.2 10.6
Berthelot linked urease 45.6 20.4 33.5 59.2
method
Inter-assay imprecision in the measurement of urea in 
gastric juice samples.
Table
Measured Urea concentration 
(SD) mmol/L
o-pthalaldehyde 0.2 (0.05)
method
Diacetylmonoxime 0.0
method
Urease method 4.2 (0.14)
not blanked
Berthelot linked urease 0.4 (0.3)
method
The effect of adding 10 mmol/L ammonium chloride 
on the measurement of urea in fasting gastric 
juice samples pH 1.38.
Table 4.6
Detection limits 
(mmol/L)
o-pthalaldehyde 0.3
method
Diacetylmonoxime 0.5
method
Urease method blanked 0.7
Berthelot linked urease 0.6
method
The detection limits of the 4 urea methods.
4) The effect of pH on the measurement of gastric juice
ammonium
Alteration of gastric juice pH over the range 2.29 to 
7.20 did not affect the measurement of ammonium (Table 
4.7). The samples were diluted 1/4 or 1/20 (prior to 
analysis) depending on the ammonium concentration with 0.2 
mol/L phosphate buffer pH 7.4. This reduced the 
concentration of ammonia in the sample to that of the 
linear range of the assay which was between 30 umol/L and 
1 mmol/L. The phosphate buffer neutralised the effects of 
gastric juice acidity. If distilled water was used as the 
diluent then the measured concentrations of ammonia were 
reduced. The inter-assay coefficient of variation of the 
enzymatic ammonia method (including dilution) using 
gastric juice samples with added ammonium chloride ranged 
from 17.2% for 2.5 mmol/L ammonium to 6.5% with 7.5 mmol/L 
ammonium (Table 4.8). The inter-assay coefficient of 
variation from a range of samples from several individuals 
ranged from 8.5% at 2.3 mmol/L to 1.5% at 11.1 mmol/L 
ammonium (Table 4.9).
The intra-assay coefficient of variation of the 
standard with 10 mmol/L ammonium concentration was 1.0% 
while the inter-assay coefficient of variation was 2.0%. 
Using samples from patients the intra-assay CV including 
dilution varied from 8.5% at an ammonium concentration of
2.3 mmol/L to 1% at an ammonium concentration of 13.0 
mmol/L.
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Table 4.7
Gastric juice ammonium 
concentration (SD) 
at a range of sample pH
pH 2.29 pH 4.04 pH 7.20 pH 2.29
Ammonium chloride
not added 0.98 0.97 0.93 0.90
(0.010) (0.016) (0.016) (0.016)
5 mmol/L added 5.5 5.0 5.4 5.2
ammonium chloride (0.14) (0.05) (0.07) (0.26)
10 mmol/L added 9.8 9.8 9.8 9.4
ammonium chloride (0.16) (0.07) (0.51) (0.26)
The absence of any effect of the pH of gastric juice samples 
on the measurement of ammonium concentration (n=5) using the 
enzymatic method adopted for the Cobas Bio (Roche, Welwyn 
Garden City, UK).
Table 4.8
Added concentration 
of ammonium
2.5mmol/L 5mmol/L 7.5mmol/L lOmmol/L
Measured concentration 3.0 5.6 7.9 10.3
of ammonium
Inter-assay CV 17.2% 9% 6.5% 9.9%
% recovery 94% 97% 95% 96%
mean initial ammonium 
concentration was
0.75 mmol/L)
The inter-assay coefficient of variation and recovery of 
the measurement of gastric juice samples to which 
ammonium chloride had been added.
Table 4.9
Gastric juice 
Ammonium concentration
Inter-assay coefficient 
of variation (%)
Gastric juice samples 
from patients
mmol/L
2.3 4.7 6.5 11.1
8.5% 1.9% 2.1% 1.5%
The inter-assay coefficient of variation in the 
measurement of gastric juice samples from several 
individuals.
The measured ammonium concentration in the samples 
was linear with serial dilution. The detection limit of 
the assay was 30 umol/L.
5) The Stability of ammonium during storage
Samples kept in a freezer at -20° also demonstrated 
no significant change in ammonium concentration over a 21 
day period.
4 .4 Discussion
The o-pthalaldehyde method and the enzymatic urease 
method, when blanked proved the most suitable methods for 
the measurement of urea. Both of these were automated 
methods and suitable for large numbers of samples. The 
berthelot method of measurement of urea did not prove 
suitable for use with gastric juice samples. Its 
imprecision, when compared with the manual diacetyl­
monoxime method suggested an interference in the method. 
This was not due to the pH of the sample because 
reconstituting the urease enzyme with 0.2mol/L phosphate 
buffer pH 7.4 instead of the deionised water in order to 
neutralise the pH of the samples did not eliminate the 
interference. It may have been due to a matrix effect of 
the gastric juice, such as the concentration of bile 
acids.
The diacetylmonoxime method of measurement of urea 
may also be suitable for use with gastric juice samples if 
care were to be taken to improve the imprecision of the 
method.
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The enzymatic ammonium method had acceptably low 
imprecision and high sensitivity. The pH of the sample 
did not interfere in measurement of ammonium 
concentration. Samples needed to be diluted with 0.2 
mol/L phosphate buffer pH 7.4 prior to analysis to bring 
the ammonia concentration to within the linear range of 
the method. Gastric juice ammonium concentrations also 
proved stable on storage at -20°C. This may have been 
due to the reduced protein content of gastric juice 
compared with plasma, the low level of enzymatic activity 
as a result of the acid pH of the sample and the trapping 
of ammonium ions in solution due to the acidity of gastric 
j uice.
The improved imprecision of ammonium measurement 
observed when samples from subjects with H pylori 
infection were compared with samples with added ammonium 
may have been the result of error in the addition of 
ammonium to replicate samples. When these samples were 
diluted prior to analysis the effect of the error in 
dilution on the result would have been magnified.
This study has demonstrated that the differing 
reports of urea concentration in gastric juice samples 
(182,194,195) should not have been the result of the use 
of different well controlled methods. It is possible that 
the report of a mean urea concentration of 4.8 mmol/L in 
samples from subjects who had infection may have been due 
to failure to use blanks to control the interference of
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endogenous ammonia in the urease method used (194). The 
method of measuring urea used by the second group which 
found mean urea concentrations of 3.27 mmol/L in samples 
from subjects with H pylori infection was not well 
described (195). The differences in reports of gastric 
juice urea and ammonium concentrations might also have 
been due to a failure to properly distinguish between 
individuals with H pylori infection and those free from 
infection.
Care also needs to be taken during the analysis of 
samples by manual methods to ensure that there is not 
unacceptable imprecision in the method. High imprecision 
could lead to apparent differences between samples due to 
analytical error.
In conclusion, differences in reports of gastric 
juice urea and ammonium concentration should not be the 
result of the use of different methods when well 
controlled. Other reasons for the reported differences 
must be sought.
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CHAPTER 5
THE DETECTION OF HELICOBACTER PYLORI 
INFECTION OF THE GASTRIC MUCOSA BY 
MEASUREMENT OF GASTRIC ASPIRATE
AMMONIUM AND UREA CONCENTRATIONS
THE DETECTION OF HELICOBACTER PYLORI INFECTION OF
THE GASTRIC MUCOSA BY MEASUREMENT OF GASTRIC ASPIRATE 
AMMONIUM AND UREA CONCENTRATIONS
5.1 Introduction
The remarkably high urease activity of Helicobacter 
pylori has been used to detect infection of the gastric 
antral mucosa by the organism. At present there are two 
methods of diagnosing H pylori infection based on its 
urease activity. One uses the detection of ammonia 
formation following incubation of an antral biopsy in a 
urea containing medium (68-71). There are several 
variants of this method. The second method requires the 
oral administration of t4C or 13C labelled urea and 
subsequent analysis of labelled C02 excreted in the 
breath (72-74). The isotopic breath tests take 1-2 h to 
complete and the final result may not be available for 
several days, while the methods based on the detection of 
urease activity may take from a few minutes to 24 h to 
complete.
The organism’s high urease activity would be expected 
to cause characteristically raised gastric juice ammonium 
concentrations and reduced gastric juice urea 
concentrations when infection was present. These findings 
have been reported by Marshall and his colleagues (182) 
but not by others (194,195).
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If there are characteristic changes in gastric juice 
then these might be used for detecting presence of the 
infection. The ability to detect this infection and to 
confirm its eradication is likely to become increasingly 
important in the management of patients with duodenal 
ulcer disease. Any new method of detection of the 
organism which used currently available laboratory based 
analytical methods and did not rely on the purchase of new 
equipment/ or reagents could therefore prove useful.
The concentrations of urea and ammonium in gastric 
juice samples from infected subjects and after the 
bacterium’s eradication were measured to establish the 
characteristic changes associated with infection. The 
usefulness of the measurement of these concentrations in 
the detection of the presence of the organism was also 
investigated. Subjects with the infection who had normal 
renal function, or who had chronic renal failure and also 
following treatment with H2 receptor antagonists were 
investigated.
5.2 Patients
1. Subjects with Duodenal Ulcers 
Twenty-seven patients (21 male, age range 18-64 
years) with a history of endoscopically proven duodenal 
ulceration were examined. Two of them were taking 
ranitidine but none had been prescribed omeprazole. All 
had normal renal function. Twelve were only examined on 
one occasion having never received any anti-H pylori
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treatment. Twelve were examined before and one month 
after completing a 4 week course of tripotassium dicitrato 
bismuthate 120 mg tid, metronidazole 400 mg tid and 
amoxycillin 250 mg tid. Three patients were examined only 
one month after the same treatment. At each time they 
were examined an upper gastrointestinal endoscopy and 
14C-urea breath test were performed. All the patients 
fasted for 16 h prior to endoscopy.
During endoscopy and just after entering the stomach 
2 ml of gastric juice was aspirated through the suction 
channel of the endoscope and collected in a trap inserted 
in the suction line. Routine inspection of the upper 
gastrointestinal tract was then performed and following 
this an antral biopsy was obtained for histological 
examination. The biopsy was fixed in formalin prior to 
staining with haematoxylin and eosin. The severity of 
histological gastritis was scored as described by Rauws 
(125) and the presence of H pylori noted.
2. Subjects with Chronic Renal Failure
A further 16 patients (9 male) with established 
chronic renal failure and dyspeptic symptoms were 
investigated to examine the effect of chronic renal 
failure on gastric juice urea and ammonium 
concentrations. Two were examined before and after 
treatment to eradicate the infection while the other 14 
patients were examined only on one occasion.
As previously described 2 ml gastric juice samples
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and antral biopsies were collected during routine upper 
gastrointestinal endoscopic examination. A 14C-urea 
breath test was also performed on each occasion a patient 
was examined. The biopsy was fixed and examined and 
inflammation scored as previously described. Only the 
peak 10 or 20 min 14C-urea breath test value was 
recorded.
3. Subjects treated with Ranitidine
A further 10 patients (3 H pylori positive, 7 
H pylori negative) were investigated for the effect of 
H 2 receptor antagonist treatment on the concentrations 
of urea and ammonium in gastric juice. A fasting sample 
of gastric juice was obtained from each patient before and 
following a 7 day course of ranitidine 300 mg nocte. The 
second gastric juice sample was collected within 14 h of 
the last dose of ranitidine.
5.3 Methods
The gastric juice samples were stored frozen at 
-20°C until analysed. Prior to analysis the samples 
were centrifuged at 3000 g for 10 min to remove the 
mucous. The concentration of ammonium was measured in the 
supernatant following dilution in 0.2 mol/L phosphate 
buffer pH 7.4 using the enzymatic method (Sigma Chemical 
Co., Dorset, UK) adapted for the Cobas Bio (Roche, Welwyn 
Garden City, UK).
Urea concentrations were measured using an automated 
urease method with a blank channel to control endogenous
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ammonia concentrations (SMAC I, Technicon, Basingstoke, 
UK). All samples were analysed blind without the 
knowledge of the presence of infection by the organism in 
individuals studied.
The 14C-urea breath tests were undertaken as 
previously described. Each breath test was performed 
within 5 days of endoscopic examination.
5.4 Results
5.5 Helicobacter pylori status of subjects studied
1) Subjects with Duodenal Ulcers
In the 24 duodenal ulcer patients who had not 
received anti-H pylori treatment, the organism was present 
in each on examination of their antral biopsy. In each 
patient with the organism antral gastritis was present and 
the median score for severity of the gastritis was 5 
(range 2-8). In 14 of the 15 patients examined one month 
after completing a course of anti-H pylori treatment 
H pylori-like organisms were not identified in the antral 
biopsies. None had gastritis scores greater than 1. In 
one patient treatment failed to eradicate the infection 
and the bacterium was still present in the mucosa and was 
associated with persistent antral gastritis with a 
severity score of 5.
Analysis of the area under the 2 hours of the breath
test showed clear separation of the patients with
histological evidence of eradication of the infection from
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patients with evidence of the infection and who had never 
received anti-H pylori treatment (Table 5.1). The values 
in the former were all less than 20 (range, 3-18) and in 
the latter all were greater than 60 (range, 63-267). In 
the one patient with histological evidence of failure of 
eradication the value was 114 before treatment and 90 
after treatment. She was therefore included only as a 
positive for H pylori in the further analysis. The higher 
single value of either the 10 min or 20 min breath test 
result was also found to clearly separate the patients 
into the two groups indicating that a shortened 20 min 
breath test could be as useful as the complete 2 h test 
(Table 5.1).
2) Subjects with Chronic Renal failure
H pylori like organisms were detected by antral 
biopsy from 4 of the 14 patients with chronic renal 
failure investigated on only one occasion. Infection was 
associated with antral gastritis with a median score of 4 
(range, 3-6). In the remaining 10 patients examined on 
only one occasion H pylori was not detected on examination 
of antral biopsy or by culture for the organism. None had 
gastritis scores greater than 1.
Two patients were examined before and after treatment 
to eradicate H pylori. Following treatment the organism 
had been eradicated from both individuals who had antral 
gastritis scores of 1 and 2.
In the H pylori positive individuals the median peak
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Table 5.1
Area under breath test curve 
Median (Range)
(% aose/mmol C02 x kg x min)
0-30 min 0-40 min 0-60 min 0-120 min Peak of 10/20
min breath 
test result 
(% dose/ 
mmol CO 2  
x kg x 100)
137
(39-225)
2.6
(0-5.1)
14C-urea breath test results from individuals with normal 
renal function.
Pre­
eradication 25 41 76 152
of H pylori (6-42) (12-69) (23-127) (63-267)
Post-
eradication 0.6 0.7 1.7 5.0
of H pylori ( 0.1-1.1)(0.3-2.5)(0.8-7.2)(3.0-18.0)
10/20 min breath test value was 146 (range, 61-584). In 
H pylori negative individuals the median value was 8 
(range, 0.09-38). The values clearly separated the two 
groups and were similar to those found in the patients 
with duodenal ulcers and normal renal function. The range 
of values for the peak 10/20 min breath test for H pylori 
negative individuals with chronic renal failure was 
greater than that of the patients with normal renal 
function but did not overlap with the values in either 
group of H pylori positive subjects. Despite this the 
highest peak 10/20 min breath test value from subjects 
with chronic renal failure who were H pylori negative was 
similar, 38, to the lowest value found in individuals with 
normal renal function, 39, who had H pylori infection.
The 10 or 20 min breath test value although useful in 
subjects with chronic renal failure may require the use of 
a second method of detecting H pylori infection for 
subjects with borderline results.
5.6 Concentrations of urea and ammonium in gastric juice 
samples
1) Subjects with Duodenal ulcers
The median (range) gastric juice urea concentration 
was 0.8 mmol/L (0.5-2.9 mmol/L) in those with the 
infection compared with 2.1 mmol/L (1.0-3.7 mmol/L) in 
patients in whom it was eradicated (p<0.001) (Fig 5.1).
The median (range) gastric juice ammonium concentration 
was 3.4 mmol/L (1.0-13.0 mmol/L) in infected individuals
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Urea concentrations (mmol/L) in gastric juice samples from
individuals before and after eradication of H pylori.
and 0.64 mmol/L (0.02 - 1.4 mmol/L) following eradication 
(p<0.001) (Fig 5.2). Although there was considerable 
overlap between the two groups with respect to their urea 
and ammonium concentrations, there was complete separation 
of the groups with the urea/'ammonium ratio (Fig 5.3). The 
median ratio in gastric juice of infected subjects was 
0.26 (0.04 - 0.7) compared with 3.4 (1.1 - 113) in those 
eradicated of the infection (p<0.001). Thus, all 
subjects with H pylori infection had a urea/ammonium ratio 
of less than 0.80 and all those eradicated of the 
infection had a ratio of more than 0.90. There was no 
correlation of the area under the 2 h breath test values 
and the gastric urea concentration, ammonium concentration 
or urea/ammonium ratio (Fig 5.4).
2) Subjects with Chronic renal failure
The median (range) serum urea concentration in those 
with the infection was 19.7 mmol/L (12.0 - 31.2 mmol/L) 
compared with 23.8 mmol/L (10.7 - 32.2 mmol/L) in patients 
without the infection (p >0.5, NS) (Table 5.2).
The median (range) gastric juice urea concentration 
in those with the infection was 2.2 mmol/L (0.5 - 8.7 
mmol/L) compared with 13.8 mmol/L (5.4 - 20.8 mmol/L) in 
non-infected individuals (p<0.001) (Table 5.2). The 
median (range) gastric juice ammonium concentration was
20.0 mmol (13.9-43.1 mmol/L) in those with the infection 
compared with 4.8 mmol/L (0.5-12.3 mmol/L) in patients 
without the infection (p<0.001). The median 
concentrations of urea and ammonium were different in the
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AREA UNDER BREATH TEST CURVE
Correlation of the area under the 120 min breath test curve 
(% dose/mmol C 0 2 kg body weight x min) with urea/ammonium
ratio in gastric juice (r = 0.004).
Table 5.2
20 min breath 
test value 
(% dose/mmol C
H pylori -ve Gastric Juice Serum Kg
subj ects Ammonium Urea Ratio Urea
1 10.9 19.3 1.8 23.1 38
2 11.4 14.1 1.2 16.7 0
3 2.0 10.6 5.3 19.4 14
4 0.5 20.8 - 32.2 0
5 4.2 7.0 1.7 25.2 10
6 0.8 15.1 18.9 28. 3 18
7 12.3 16.9 1.4 27.1 27
8 5.4 5.4 1.0 10.7 14
9 11.5 18.5 1.6 23.6 5
10 2.6 12.7 4.9 22.5 1
11 3.3 9.3 2.5 20.5 34
12 11.4 13.4 1.2 24.0 5
H pylori +ve 
subj ects 
1 13.9 0.5 0.01 28.3 584
2 43.1 3.0 0.07 31.2 150
3 16.1 0.6 0.04 12.0 174
4 30.0 8.7 0.30 18.3 106
11 18.9 1.4 0.07 14.2 61
12 21.0 7.3 0.35 20.5 87
The effect of chronic renal failure on gastric juice
urea and ammonia concentrations and the urea/ammonium ratio.
two groups of patients with renal failure but there was 
again overlap between those with the infection and 
patients in whom it was not present or had been 
eradicated. There was also overlap between the 
concentrations of urea in gastric juice from H pylori 
negative individuals with normal renal function and 
H pylori positive individuals with chronic renal failure.
When the urea/ammonium ratio was calculated the 
median value for H pylori positive subjects was 0.16 
(range, 0.01-0.35) compared with 1.63 (range, 1.0 - 18.9) 
for H pylori negative subjects (p<0.001).
Again, all subjects with infection with H pylori had
a urea/ammonium ratio of less than 0.80 and all those in
whom it had been eradicated or was not present had a ratio 
of 0.90 or greater.
3. Subjects treated with Ranitidine
In the 10 patients studied before and following 7 
days treatment with ranitidine there was no change in the 
gastric juice concentrations of urea or ammonium or their 
ratio (Table 5.3). Using a urea/ammonium ratio of 0.80 or 
less as indicative of infection treatment with ranitidine 
did not alter the classification of H pylori status in any 
subjects studied.
5. 7 Discussion
The 14C-urea breath test has been used to detect
the presence of H pylori by its urease activity (72,73).
This test is reproducible and is a sensitive method of
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Table 5.3
Pre-treatment
H pylori -ve
Subjects Ammonium Urea Ratio
1 2.0 2.9 1.4
2 2.2 3.1 1.4
3 2.0 4.3 2.1
4 0.8 2.2 2.6
5 1.6 2.5 1.6
6 1.4 2.0 1.4
7 2.2 2.1 0.9
H pylori +ve 
Subj ects
1 6.1 1.2 0.2
2 8.8 2.0 0.2
3 7.2 0.6 0.1
During Ranitidine 
Treatment
Ammonium Urea Ratio
1.9 2.6 1.3
2.9 2.6 0.9
2.5 3.0 1.2
2.0 2.7 1.3
2.8 3.0 1.1
1.2 1.9 1.6
2.5 2.6 1.0
5.7 1.4 0.2
5.2 1.6 0.3
8.4 0.2 0.1
The effect of 7 days' treatment with Ranitidine 300 mg 
nocte on the concentrations of urea and ammonium and 
their ratio in gastric juice.
detecting infection of the antral mucosa with H pylori.
The test does have several disadvantages. It takes 2 h to 
complete using the standard protocol although a shortened 
40 min test has been proposed (227). The data from the 
patients with duodenal ulcers indicated that using the 
highest of the 10 or 20 min values would be as effective 
as the calculation of the area under the 120 min of the 
breath test curve. This was confirmed by the data from 
patients with chronic renal failure in whom the separation 
of the 2 groups identified by biopsy and culture of the 
organism was reproduced by the 10 or 20 peak breath test 
value. The highest 10/20 min peak breath test value from 
H pylori negative individuals with chronic renal failure 
was similar to the lowest value from H pylori positive 
individuals with normal renal function. This suggests 
that the 10/20 min peak breath test value could not be 
used on its own for the detection of the organism. Two 
methods of detecting the bacterium would be needed but 
this is standard practice even for the complete breath 
test.
This study has also demonstrated that the urease 
activity of the organism results in reduced urea and 
increased gastric juice ammonium concentrations. The 
range of concentrations found overlapped between 
individuals with the organism and individuals who were not 
infected. The concentrations of these two analytes also 
varied considerably with the availability of urea. Higher 
concentrations of both urea and ammonium were found in 
individuals with chronic renal failure. The gastric juice
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urea concentrations in some samples from patients with 
H pylori infection and renal failure were higher than 
those found in some individuals without the infection but 
with normal renal function. Treatment with the H2 
receptor antagonist ranitidine did not alter the 
concentrations of urea and ammonium in gastric juice 
samples.
Calculation of the ratio of urea to ammonium in 
gastric juice did clearly discriminate between those with 
the infection and patients clear of infection. The ratio 
also distinguished between these groups in the presence of 
chronic renal failure and also following treatment with 
ranitidine. The discriminating ability of this ratio can 
be explained by the inverse effect that the organism's 
urease activity exerts on urea and ammonium concentrations 
in gastric juice.
Although the urea/ammonium ratio was as effective as 
the 14C-urea breath test at distinguishing between 
patients with the infection and those in whom it had been 
eradicated there was no correlation between urease 
activity as assessed by the urea breath test and the ratio 
of urea to ammonium concentrations in gastric juice. The 
absence of a correlation may be explained as follows. The 
14C-urea breath test is a dynamic test measuring the 
response of the enzyme to a urea load, while the 
urea/ammonium ratio is a measure of basal H pylori urease 
activity. The rate of ammonia production in infected
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individuals is mainly dependent on the availability of 
urea. This was demonstrated by the higher gastric juice 
ammonia concentrations found in patients with chronic 
renal failure.
The raised gastric juice ammonium concentrations in 
samples from subjects with the infection (1.0-13.0 mmol/L) 
and especially in those with chronic renal failure 
(13.9-43.1 mmol/L) indicated that the organism’s urease 
activity might possibly produce sufficient ammonia to 
raise the surface pH of the antral epithelium. This might 
be responsible for the increase in plasma gastrin 
concentration with infection which has been demonstrated 
following eradication of the organism (19-26).
In conclusion infection with the organism results in 
reduced gastric juice urea concentrations and raised 
ammonium concentrations. The concentration of ammonium in 
gastric juice depends on the availability of gastric juice 
urea. The measurement of the ratio of gastric juice 
concentrations of urea and ammonium in fasting gastric 
juice samples provides another simple method of 
determining H pylori status in patients with duodenal 
ulcers.
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CHAPTER 6
THE EFFECT OF STIMULATING OR INHIBITING 
HELICOBACTER PYLORI UREASE ACTIVITY ON
GASTRIN CONCENTRATION
THE EFFECT OF STIMULATING OR INHIBITING HELICOBACTER
PYLORI UREASE ACTIVITY ON GASTRIN CONCENTRATION
6.1 Introduction
The eradication of chronic Helicobacter pylori 
infection of the gastric antrum which is present in more 
than 95% of patients with duodenal ulcer disease reduces 
the duodenal ulcer relapse rate from 80% to 20%
(144-146). The eradication of this infection is also 
accompanied by a lowered circulating gastrin concentration 
(19-26). The fasting gastrin concentration falls by 
27%-33% and the integrated gastrin response to a meal by 
30-58%. The increase in circulating gastrin concentration 
associated with infection is associated with increased 
intragastric acidity during meals (25) and may therefore 
be the link between chronic H pylori infection and the 
development of duodenal ulcer disease.
The mechanism by which H pylori raises serum gastrin 
concentration is not known. It is possible that H pylori 
causes increased gastrin concentrations through its 
abundant urease activity. The organism's urease activity 
produces high gastric juice ammonium concentrations 
(median 3.4, range 1.0-13.9 mmol/L). Ammonium 
concentrations in the region of the gastric antral 
epithelial surface may be higher than in gastric juice 
samples as the organism colonises the surface of the
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antral mucosa. The production of large amounts of ammonia 
by the bacterium at the antral epithelial surface could 
increase gastrin release by any of three theoretical 
mechanisms. Ammonia is a moderately strong base and could 
therefore prevent the physiological inhibition of gastrin 
release by neutralisation of gastric acid (228). In 
addition, elevation of antral surface pH by ammonia could 
facilitate the entry of dietary amines into the antral 
G cells and thereby their stimulation of gastrin release 
(186-190). Thirdly, ammonia could directly stimulate 
gastrin release as has been shown to occur in the rat 
(186). In order to determine whether the raised plasma 
gastrin concentration was due to ammonia production by 
H pylori the effect of stimulating ammonia production by 
intragastric infusion of urea, and the effect of 
inhibiting ammonia production by administering 
acetohydroxamic acid, on plasma gastrin concentration was 
studied.
6.2 Intragastric Urea infusion experiments
6.3 Patients
Eight patients (5 male) with a history of 
endoscopically confirmed duodenal ulceration within the 
previous year were studied. Their ages ranged from 26-62 
years. Each of the patients had H pylori infection of the 
gastric antrum confirmed by histology of antral biopsies, 
rapid urease test (CLO test) and 14C-urea breath test.
None had taken any acid inhibiting agents or bismuth 
preparations in the month prior to commencement of the 
study.
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6.4 Methods
The plasma gastrin response to increasing ammonia 
production was investigated by infusing a urea solution 
into the gastric antrum. Each patient acted as their own 
control by having the urea infusion repeated one month 
after a three week course of tripotassium dicitrato 
bismuthate (DeNol tab) 120 mg qid, and metronidazole 400 
mg tid designed to eradicate H pylori. Confirmation of 
eradication was obtained by repeating the endoscopic 
antral biopsies and 14C-urea breath test one month after 
completion of therapy.
Following a 16 h overnight fast a dual-lumen size 16F 
gastric tube (Anderson Inc., New York) was passed 
nasogastrically and positioned radiographically so that 
its tip lay in the distal part of the stomach. An 
intravenous cannula was inserted into the antecubital 
vein. At the end of a 30 min basal period, the stomach 
was emptied and over the following hour dextrose solution 
(328 mmol/L) which did not contain urea was infused into 
the stomach at a rate of 2 ml per minute. Following this 
control period, dextrose solution containing urea, 50 
mmol/L was infused at a rate of 2 ml per minute for 4 
hours. The concentrations of dextrose in the urea 
solution was reduced by 50 mmol/L so that the osmolalities 
of the two solutions were the same. In addition the pH of 
the solutions were reduced to 1.8 by adding 1 ml 
concentrated HCL per 500 ml dextrose to prevent them 
raising intragastric pH.
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Venous blood samples were obtained at 30 minute 
intervals through the experiment for measurement of plasma 
gastrin concentration. The blood was centrifuged at 3000 
g for 10 minutes at 4°C and the plasma stored at 
-20°C. During the intragastric infusions 10 ml samples 
of gastric juice were collected every 15 minutes for the 
measurement of ammonium and urea concentrations and 
determination of pH. At the end of each hour all the 
gastric contents were aspirated to prevent accumulation of 
infusate.
Plasma gastrin concentrations were measured as 
previously described. The concentration of urea in 
gastric juice was measured by a blanked automated urease 
method using the SMAC I (Technicon, Basingstoke, UK). The 
ammonium concentration was measured by an enzymatic method 
adapted for the Cobas Bio (Sigma, Dorset, UK).
Statistical analysis was by means of the Wilcoxon signed 
rank-sum test. The study had the approval of the Western 
Infirmary Ethical Committee and each patient gave written 
informed consent.
6.5 Results
6.6 The effect of stimulating urease activity by
intragastric infusion of urea
The infection by H pylori was successfully eradicated 
in 7 of the patients. Clearance of the infection was 
confirmed by resolution of gastritis on antral biopsies 
and a fall in the 14C-urea breath test 20 min value to
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less than 20 percentage dose/mmol COz x kg body wt x 100 
at four weeks after completion of the antibacterial 
treatment. The urea/ammonium ratios were also all greater 
than 0.9 in the basal samples collected during the 
post-eradication infusion studies. The patient in whom 
the organism was not cleared was excluded from further 
analysis.
6.7 Basal Values
The median concentration of ammonium ions in the 
basal gastric aspirate prior to eradication of H pylori 
was 4.4 mmol/L (range 1.8-14.7) and this fell following 
eradication to 0.7 mmol/L (range 0.3-1.4) (p<0.02) (Fig 
6.1). The median concentration of urea in the basal 
gastric aspirate was 1.1 mmol/L (range 0.3-1.6) and rose 
to 2.5 mmol/L (range I.0-3.4) following eradication 
(p<0.02) (Fig 6.1). The median plasma concentration of 
gastrin was 30 ng/L (range 15-60) and this fell to 20 ng/L 
(range 15-25) (p<0.05) following eradication (Fig 6.1).
The median pH of the basal gastric aspirates did not 
change significantly being pH 1.7 (range 1.2-1.9) before 
and 1.6 (range 1.2-1.7) following eradication.
6.8 The effect of the intragastric infusions
During the 60 minute control infusion of dextrose 
solution both before (Fig 6.2) and after eradication (Fig 
6.3) there was a progressive fall in urea and ammonium 
concentrations in the gastric aspirate due to dilution by 
the infusate. Plasma gastrin concentration did not change 
over this period.
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concentrations before and after eradication of H pylori infection in 7 
duodenal ulcer subjects.
Following eradication plasma gastrin concentration and gastric juice 
ammonium concentrations were lower (p <0.05, p <0.02 respectively) 
and gastric juice urea concentration increased (p <0.02).
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Prior to eradication of H pylori the urea infusion 
resulted in a rise in the gastric aspirate urea 
concentrations which reached a plateau after 60 min at a 
median value of 15.5 mmol/L (range 7.9-21.3) (Fig 6.2).
The median gastric juice ammonium concentration 
immediately prior to commencing the urea infusions was 2.3 
mmol/L (range 1.3-5.9) and rose over 90 minutes to reach a 
median plateau value of 6.1 mmol/L (range 4.2-11.9). This 
rise in ammonium production was not accompanied by any 
change in plasma gastrin concentration (Fig 6.2).
Following eradication of H pylori the rise in gastric 
juice urea concentration during urea infusion was similar 
to that prior to eradication (Fig 6.3). On this occasion 
there was no rise in the ammonium concentration with the 
median value immediately prior to commencing the infusion 
being 0.4 mmol/L (range 0.1-0.9) and 0.4 mmol/L (range 
0.3-1.2) at the end of the infusion. The median gastrin 
concentration which was lower following eradication of 
H pylori was unaffected by the urea infusion.
The pH of gastric aspirates remained between 1.5 and
2.0 throughout the pre and post eradication studies.
6.9 Discussion of the intragastric infusion study
In agreement with previous work this study 
demonstrated that there was a reduction in plasma gastrin 
concentrations following eradication of H pylori infection 
in duodenal ulcer subjects (19-26). Increased H pylori 
ammonia production failed to alter plasma gastrin
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concentration. This observation does not lend support to 
the hypothesis that hypergastrinaemia is caused by the 
ammonia. It seems likely that the increase in ammonia 
production resulted in an adequate stimulus as the rise in 
ammonium concentration at the antral epithelial surface 
where the bacteria are found close to the gastrin 
secreting G ceils would have been greater than the 3 fold 
rise observed in the gastric aspirate. However, failure 
to cause a further increase in gastrin concentration does 
not exclude the possibility that the elevated basal 
gastrin concentrations were due to the bacterium's ammonia 
production. The amount of ammonia produced by the 
organism under normai circumstances might be sufficient to 
produce the maximum gastrin response through alteration of 
the antral surface pH or by any direct effect on the 
gastrin producing cells. The mechanism through which 
H pylori raises plasma gastrin concentrations, therefore, 
remained to be determined.
6.10 The effect of inhibition of urease activity by 
acetohydroxamic acid
6.11 Patients with Helicobacter pylori infection 
Six patients (3 males) who had endoscopically
confirmed duodenal ulceration within the previous year but 
were in remission at the time of the study were 
investigated. Their ages ranged from 26-52 years. In 
each patient an antral biopsy obtained endoscopically
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within the preceding 3 months had shown gastritis 
associated with H pylori-like organisms. None had taken 
any acid inhibitory agents or bismuth preparations in the 
month prior to commencement of the study.
6.12 Method
On the first morning of the study the patients having 
fasted for 16 h overnight had a venous blood sample 
removed at 0800 h for gastrin measurement. Immediately 
following this they drank 50 ml of water and 4 further 
blood samples were collected at 30 min intervals for the 
next 2 hours. At 1000 h they took a standard meal 
consisting of 2 beef cubes (0X0 Ltd., Croydon, England) 
dissolved in 200 ml water at 50°C. Further blood 
samples were collected at 10 min intervals for 70 min and 
a final sample was collected at 90 min following the 0X0 
drink. Immediately following this sample a 14C-urea 
breath test was conducted to measure H pylori urease 
activity.
On the following day the study was repeated in an 
identical fashion except that the patients received 750 mg 
acetohydroxamic acid (Lithostat, Mission Pharmacol, USA) 
with a 50 ml drink of water at 0800 h.
Ten days later a third 14C-urea breath test was 
performed to determine whether the temporary inhibition of 
urease activity had resulted in clearance of the 
infection.
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6.13 Patients without Helicobacter pylori infection
Two male patients (aged 25 and 52 years) with a past 
history of duodenal ulcer disease but in whom H pylori had 
been eradicated within the previous year were studied in 
an identical fashion to that described above. This was 
conducted in order to exclude the possibility that 
acetohydroxamic acid might have a direct effect on gastrin 
release.
6.14 Study in Healthy Volunteer with Helicobacter pylori 
infection
The effect of acetohydroxamic acid on the 
concentrations of urea and ammonium in gastric juice was 
examined in a single healthy volunteer (AN aged 32 years)
with H pylori infection. Endoscopic antral biopsy 3
months earlier had demonstrated gastritis and 
H pylori-like organisms. A 14C-urea breath test
performed one month prior to the study gave a 20 min value
of 109 percentage dose/mmol CO? x kg body wt x 100 which 
is in the range for infected subjects (60-267) found in 
the previous studies.
He reported fasted at 0800 and a nasogastric tube was 
passed per orally. The resting gastric juice was 
aspirated and discarded and then constant suction was 
applied. At 30 min suction was discontinued to allow for 
the manual aspiration of a 5 min gastric juice sample.
A further gastric juice sample was similarly 
collected at 60 min. Following this 750 mg
85
acetohydroxamic acid was taken with 50 ml of water and no 
suction was applied until 1 h later when all the resting 
volume was aspirated but a 5 ml portion was retained for 
ammonium and urea analyses. Suction was recommenced but 
temporarily discontinued every 30 min over the following 
3.5 h to allow manual aspiration of 5 ml samples of 
gastric juice.
6.15 Analytical methods
Plasma gastrin concentrations were measured by a 
radioimmunoassay (CIS (UK) Ltd, Buckinghamshire, UK). All 
samples from each patient were analysed in the same 
batch. The concentration of urea in gastric juice samples 
was measured by the o-pthalaldehyde method using a 
Perspective analyser (American Monitor, West Sussex, UK). 
The concentration of ammonium was measured by an enzymatic 
method (Sigma, Dorset, UK) adapted for the Cobas Bio 
centrifugal analyser. The integrated gastrin response to 
the 0X0 meal was calculated using the trapezoid rule. 
Statistical analysis used the Wilcoxon signed rank-sum 
test. The study was approved by the Western Infirmary 
Ethical Committee and each subject gave written informed 
consent.
6.16 Results of the inhibition of urease activity with
acetohydroxamic acid
The initial median breath test value was 152 
percentage dose/mmol C02 x kg body wt x 100 (range
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111-335) compared with 22 (range 14-95) on the second day 
of the study following the administration of 
acetohydroxamic acid (p<0.03) (Fig 6.4). Ten days after 
the administration of acetohydroxamic acid the median 
breath test value was 149 (range 126-257) which was 
similar to the pre-treatment value (Fig 6.5).
Although there was suppression of H pylori urease 
activity following the administration of acetohydroxamic 
acid there was no difference between the two study days 
with respect to the basal or meal stimulated plasma 
gastrin concentrations (Fig 6.6). The initial median 
integrated gastrin response to the 0X0 meal 'was 78 ng/L.h 
(range 21-222) compared with 79 ng/L.h (range 33-207) 
following acetohydroxamic acid (Fig 6.7).
The basal and meal stimulated gastrin responses in 
the patients without H pylori infection were unaffected by 
administration of acetohydroxamic acid.
The administration of acetohydroxamic acid to the 
healthy volunteer who had H pylori infection resulted in a 
rise in the urea concentration in the gastric juice. The 
ammonium concentrations prior to administration of the 
inhibitor were 5.2 mmol/L and 5.5 mmol/L in the two basal 
gastric juice samples. One hour following administration 
of the inhibitor the gastric juice ammonium concentration 
had fallen to 2.0 mmol/L and then ranged from 1.9 - 3.6 
mmol/L (Fig 6.8). The ratio of urea/ammonium in gastric 
juice prior to the urease inhibitor was 0.2 but in 5 of
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the 6 samples collected following the inhibitor was 
greater than 1.0. None of the patients experienced side 
effects following the administration of acetohydroxamic 
acid.
6.17 Discussion of inhibition of urease activity with
acetohydroxamic acid
Acetohydroxamic acid is usually used to reduce 
bacterial ammonium production in patients with renal 
calculi due to chronic urinary tract infection by 
inhibiting urease activity (229). Acetohydroxamic acid 
inhibits urease activity non-competitively with two 
molecules binding to each urease molecule (230). This 
binding results in conformational change and loss of 
activity. Usually the drug is prescribed in a dose of 250 
mg four times a day to achieve prolonged inhibition. In 
this study the drug was administered as a single dose of 
750 mg to achieve rapid and effective inhibition of urease 
activity.
Effective inhibition of urease activity was 
demonstrated by the 5-fold reduction in the 30 minute 
values of the 14C-urea breath test. Gastric juice 
concentrations of ammonium also fell and urea 
concentrations increased. The urea/ammonium ratio changed 
from 0.2 prior to administration of the inhibitor, which 
is in the range of infected subjects (0.04-0.8), to 1.2 
which is in the range for non-infected subjects (0.9-113).
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The altered urea/ammonium ratio occurred within 1 
hour of administration of the inhibitor and persisted for 
the remaining 3.5 h of the study. Acetohydroxamic acid is 
rapidly absorbed from the gastrointestinal tract and 
reaches peak plasma concentrations at 60 minutes with a 
plasma half life of 3.5-5 hours (231).
Despite the fall in urease activity no change in the 
basal gastrin concentration or the meal stimulated gastrin 
response was observed following the administration of 
acetohydroxamic acid. There was also no change in gastrin 
concentrations in the two H pylori negative subjects which 
excluded the possibility that a fall in gastrin had been 
masked by a direct gastrin stimulatory effect of the 
acetohydroxamic acid.
This further observation that inhibition of H pylori 
ammonia production does not lower plasma gastrin 
concentration does not lend support to the hypothesis that 
the hypergastrinaemia is a direct result of bacterial 
urease activity.
6.18 Conclusion
6.19 The result of stimulating or inhibiting 
Helicobacter pylori urease activity 
Neither the intragastric infusion of urea to
stimulate urease activity nor the inhibition of urease 
activity with acetohydroxamic acid had any effect on 
plasma gastrin concentration.
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It was unlikely that any late gastrin response in 
either of these experiments had been missed. The urea 
infusion was continued for 4 hours and a rise in gastrin 
response to direct alkalinisation of the antrum has been 
observed by this time (232). A fall in serum gastrin 
concentration would be expected within the 3.5 h period of 
inhibition of urease activity studied following 
administration of acetohydroxamic acid.
If alkalinisation of the gastric antrum by H pylori 
urease activity caused increased plasma gastrin 
concentrations then these should fall rapidly following 
inhibition of bacterial urease activity. Patients with 
hypergastrinaemia secondary to achlorhydria have a fall in 
serum gastrin concentration within 5 to 15 minutes of 
intragastric instillation of hydrochloric acid (233). 
Similarly, in healthy subjects the intragastric 
administration of acid at the same time as a meal 
suppresses or abolishes the gastrin response to the meal 
(228) .
These two studies indicate that H pylori associated 
hypergastrinaemia is unlikely to be due to the creation of 
an alkaline environment in the region of the antral G 
cells. This suggests that either the organism does not 
produce sufficient ammonia to significantly alter the pH 
of the antral epithelial surface or that alkalinisation of 
the gastric antrum by any means should not change plasma 
gastrin concentration.
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The low concentrations of urea found in gastric juice 
prior to eradication of the organism and the rapid rise in 
gastric ammonium concentration during urea infusion 
indicated that the generation of ammonia by the organism's 
urease activity was limited by the concentration of urea 
in the stomach and its rate of diffusion into the 
stomach. If the function of the urease activity is to 
create an alkaline environment to protect the organism 
from low gastric pH then such a protective mechanism 
should be able to respond to changes in gastric pH rather 
than be limited by substrate availability. Similarly in 
spite of marked suppression of urease activity by 
acetohydroxamic acid the infection was not cleared in any 
of the subjects studied as shown by the breath test 10 
days after administration of acetohydroxamic acid.
In conclusion ammonia production does not seem to be 
important in protecting the organism once infection is 
established in the deep mucous layer. Stimulation and 
inhibition of ammonia production by the organism also 
failed to produce any change in basal or meal stimulated 
gastrin concentrations. The mechanism by which H pylori 
raises plasma gastrin concentrations, therefore, remains 
unclear.
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CHAPTER 7
THE EFFECT OF DIRECT ALKALINISATION OF 
THE GASTRIC ANTRUM ON HELICOBACTER PYLORI 
RELATED HYPERGASTRINAEMIA
THE EFFECT OF DIRECT ALKALINISATION OF THE GASTRIC ANTRUM
ON HELICOBACTER PYLORI RELATED HYPERGASTRINAEMIA
7.1 Introduction
It has been proposed that the ammonia produced by 
Helicobacter pylori urease activity raises antral surface 
pH and as a result stimulates gastrin release (19). In 
previous studies the stimulation of ammonia production 
through intragastric infusion of urea and the inhibition 
of ammonia production by the administration of the urease 
inhibitor acetohydroxamic acid, failed to alter basal 
gastrin concentrations or the meal stimulated gastrin 
response. These observations fail to support the 
hypothesis that an increase in antral surface pH resulting 
from urease activity causes the increased gastrin 
concentrations found in subjects with duodenal ulcers. 
However, it is possible that the means used to alter 
ammonia production did not sufficiently alter antral pH 
and as a result did not produce an observable change in 
gastrin concentration.
If the amount of ammonia produced by the bacterium 
was, under ordinary circumstances, sufficient to produce a 
maximal gastrin response then increasing ammonia 
production would not cause a further increase in gastrin 
concentration. In the inhibition experiments the 
administration of acetohydroxamic acid while producing a
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significant reduction in the response to the 14C-urea 
breath test did not suppress it to the values found in 
non-infected individuals. It is possible therefore that 
sufficient urease activity remained uninhibited and as a 
result there was no observed change in basal gastrin 
concentrations or the meal stimulated gastrin response.
The effect of acute alkalinisation of the antrum on 
gastrin release is also not clear because some studies 
show an increased release of the hormone (232-234) but 
others no change (235-239). The reason for this is not 
known, but the conflicting reports might be explained by 
differing H pylori status of the groups studied.
If H pylori infection does cause gastrin release 
through increasing the antral pH then the difference 
between infected and non-infected subjects should be 
reduced or eliminated by the alkalinisation of the gastric 
antrum. The influence of H pylori infection on the 
gastrin response to antral alkalinisation under both basal 
and meal stimulated conditions in duodenal ulcer patients 
was therefore investigated.
7.2 Patients
Eight patients (7 male, age range 32-60 years) with 
endoscopically confirmed duodenal ulceration within the 
previous year were entered into the study. Infection with 
H pylori was confirmed by the rapid urease test (CLO 
test), histology of antral biopsy and 14C-urea breath
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test. None of the patients had taken acid inhibitory 
agents for 2 weeks before entry into the study.
7.3 Methods
In all patients the gastrin response to a standard 
test meal at uncontrolled pH and at a pH greater than 6.0 
was compared before and after eradication of H pylori. In 
six patients the gastrin response to 5 hours of 
alkalinisation of the gastric antrum was studied before 
and after eradication of H pylori.
Initially, the gastrin response to a standardised OXO 
meal was measured. The meal was prepared by dissolving 2 
0X0 cubes (0X0 Ltd. Croydon, England), in 200 ml of water 
at 50°C. This was drunk over 5 minutes. Three basal 
venous blood samples were collected at 15 minute intervals 
prior to the meal. Further venous blood samples were 
collected 5 minutes after completion of the meal and at 10 
minute intervals after that for 90 minutes. On the second 
day of the study within 7 days of the initial 0X0 meal the 
effect of gastric alkalinisation with the same 
standardised test meal was measured. A 16F dual lumen 
tube was passed orogastrically (Andersen Inc., New York), 
the stomach was emptied and a sample of gastric juice 
retained for measurement of pH. At the same time a blood 
sample was collected for measurement of plasma gastrin. 
Further samples of gastric juice and venous blood were 
collected at 15 minute intervals over the next 30 
minutes. At the end of this period the stomach was
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emptied and an intragastric infusion of 0.2 mol/L pH 7.0 
citrate buffer (530 mmol/L) was commenced at a rate of 4 
ml/min. One hour after this was started the standard OXO 
meal was consumed over 5 minutes. The infusion was 
continued for a further 10 minutes and 20 ml samples of 
gastric juice were collected over 20 minutes for pH 
measurement with a glass electrode (Radiometer ETS 822). 
Venous blood samples were collected every 15 minutes for 
gastrin measurement.
In 6 of the 8 patients the gastrin response to 
gastric alkalinisation alone was assessed. An orogastric 
tube was passed and basal gastric juice and venous blood 
samples collected as described above. An intragastric 
infusion of 0.2 mol/L pH 7.0 citrate buffer was commenced 
at a rate of 4 ml/min and continued for 5 h. Samples of 
blood and gastric juice were collected every 30 minutes 
for measurement of plasma gastrin and gastric juice pH.
The stomach was completely emptied at the end of each hour 
to prevent distension.
Following completion of these studies patients were 
commenced on a 3 week course of tripotassium dicitrato 
bismuthate 120 mg four times per day, metronidazole 400 mg 
three times per day and amoxycillin 500 mg three times per 
day, designed to eradicate H pylori. One month after 
completion of anti-H pylori treatment evidence of 
infection was sought by the rapid CLO test, antral biopsy 
and histology and the 14C-urea breath test. After this 
the plasma gastrin response to the standard 0X0 meal with
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and without gastric alkalinisation and to gastric 
alkalinisation alone was reassessed.
Samples for gastrin analysis were analysed in the 
same batch as previously described (226). Statistical 
significance was tested using the Wilcoxon signed rank sum 
test. The study was approved by the Western Infirmary 
Ethical Committee and each patient gave written informed 
consent.
7.4 Results
Eradication of H pylori had been achieved in all the 
patients when they were re-examined one month after 
completing triple therapy. The 14C-urea breath test 20 
minute value fell from a median pre-treatment value of 126 
(range 55-266) to 4 (range 2-8) one month after completion 
of treatment. The rapid urease test was positive within 5 
hours in all eight patients prior to treatment and 
negative at 24 hours in all of the patients when 
reassessed one month after completion of treatment.
The basal concentration of plasma gastrin measured on 
the day the test meal was given without alkalinisation 
fell from a median of 57 ng/L (range 13-103) pre-treatment 
to 42 ng/L (range 12-80) (p<0.05) post-treatment. The 
median integrated gastrin response to the test meal 
without alkalinisation was 2525 ng/L/min (range 55-8725) 
pre-treatment and fell to 725 ng/L/min (range 250-2925) 
following eradication (p<0.01)(Fig 7.1). On the day the
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Plasma gastrin response to oxo meal at uncontrolled pH, before and 
one month after eradication of H pylori in 8 patients.
meal was administered with alkalinisation the infusion of 
citrate buffer raised the intragastric pH to greater than 
pH 6.0 within 30 minutes of commencement and this was 
maintained for the duration of the study. The median 
integrated gastrin response to the test meal with 
alkalinisation was 3700 ng/L.min (range 1900-14100) 
pre-treatment and fell to 1400 ng/L.min (range 400-3400) 
one month after completion of treatment (p<0.01)(Fig 7.2).
Alkalinisation of the stomach resulted in a rise in 
the integrated gastrin response to the test meal in 6 of 
the 8 patients both before and after eradication of 
H pylori. The median percent change in the 8 patients was 
+73% (range -63 to + 500%) pre-treatment compared with 
+ 48% (range -26 to +386%) (NS, p=0.9) post treatment.
After eradication of H pylori the median fall in the 
integrated gastrin response to the test meal alone was 69% 
(range 36-89%) and was similar to that seen with the test 
meal plus gastric alkalinisation, 61% (range 0-97%).
When the effect of gastric alkalinisation alone was 
studied there was a rise in the plasma gastrin 
concentration in 4 of the 6 patients before and in the 
same number after eradication of H pylori. Two patients 
did not respond to gastric alkalinisation with a change in 
plasma gastrin concentration. The median plasma gastrin 
concentration after 5 hours of alkalinisation was greater 
before, (62 ng/L, range 50-165), than after, (50 ng/L, 
range 25-75), eradication of H pylori (p<0.02)(Fig 7.3). 
The median percentage change in gastrin with
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Plasma gastrin response to oxo meal at near neutral pH, before and one 
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alkalinisation alone was similar before, 47% (range 0-267) 
and after 16% (range 0-100) eradication of H pylori (NS,
p=0.2) .
7.5 Discussion
There are conflicting reports on the effect of 
alkalinisation of the antrum during fasting on gastrin 
release in man. Several investigators have reported that 
acute elevation of antral pH does not alter plasma gastrin 
concentration (235-238). Others have failed to observe 
any change in gastrin following more prolonged antral 
alkalinisation for 3 hours (239) and for up to 10 hours 
(240) in duodenal ulcer subjects. Peters and colleagues 
reported that maintaining antral pH above 6.0 for 5 hours 
produced an increase in serum gastrin of 23-30% (from 53 
pg/ml to 71 pg/ml) in duodenal ulcer subjects and 50%
(from 25 pg/ml to 38 pg/ml) in healthy controls (232). 
Similarly Hausky and colleagues reported an increase in 
serum gastrin in duodenal ulcer subjects and healthy 
controls which occurred after only 30 minutes of 
alkalinisation (234). These differing studies occurred 
before the effect of H pylori infection on gastrin release 
was appreciated.
In this study the observation that eradication of 
H pylori infection results in a fall in both basal and 
meal stimulated gastrin concentrations was again confirmed 
(19-26). In addition the different response to the test 
meal from H pylori infected and treated individuals was
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not eliminated by maintaining the intragastric pH greater 
than pH 6.0 by buffer infusion. Administration of a 
standard 0X0 meal without infusion of citrate buffer only 
raised the intragastric pH to above pH 2.0 for less than 
15 minutes (241). It has been hypothesised that H pylori 
raises plasma gastrin concentrations by the blocking of 
the inhibitory effect of gastric acid on gastrin release 
through the production of large quantities of ammonia 
close to the gastric epithelial surface (19). If the 
hypothesis was correct then the difference between 
H pylori positive and negative individuals should be 
largely or completely eliminated when a near neutral 
intragastric pH is maintained. The observation that this 
does not occur indicates that infection with H pylori does 
not result in a raised antral surface pH. It also 
confirms the earlier observations that stimulating ammonia 
production by urea infusion, or inhibiting ammonia 
production by the administration of acetohydroxamic acid 
did not alter gastrin concentrations.
Five hours of gastric alkalinisation alone caused a 
similar increase in plasma gastrin concentration before 
47% and after 16% eradication of the organism. The 
demonstration of a gastrin response to prolonged 
alkalinisation indicates that it is unlikely H pylori 
creates a significant alkaline microenvironment by 
production of ammonia. It also demonstrates that if the 
production of an alkaline microenvironment caused gastrin
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release then the stimulus from ammonia production through 
urea infusion should have been sufficient to cause an 
increase in gastrin concentration as there was sufficient 
gastrin reserve to respond to direct alkalinisation using 
the buffer.
If the raised gastrin concentrations found in 
subjects with H pylori infection does not occur through 
alteration of the antral mucosal pH, or promotion of amine 
uptake then other mechanisms need to be considered. 
Eradication of infection results in resolution of antral 
gastritis and it is possible that it is the inflammatory 
cell infiltrate in the region of the G cells which is 
responsible for the increased gastrin concentrations. One 
study has suggested that gastrin concentrations correlate 
better with antral gastritis than with H pylori infection
(242). The gastritis associated with the infection could 
also be partly due to the damaging effects of ammonia 
making it difficult in practice to differentiate the 
effects of the two (167,181).
These observations demonstrate that the effect of 
infection with H pylori on plasma gastrin concentration 
was not the result of an antral alkaline
microenvironment. The fact that plasma gastrin was also 
shown to respond to prolonged alkalinisation indicated 
that it is unlikely that H pylori creates an alkaline 
microenvironment under the antral mucosal layer in order 
to survive when it colonises the stomach. As a result
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other possible functions of the organism's urease activity 
need to be examined. The usual role of urease activity in 
many micro-organisms is to allow the organism to scavenge 
nitrogen from a urea rich environment.
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THE EFFECT OF PH AND UREASE ACTIVITY ON THE 
IN VITRO SURVIVAL OF HELICOBACTER PYLORI
THE EFFECT OF PH AND UREASE ACTIVITY ON THE IN VITRO
SURVIVAL OF HELICOBACTER PYLORI
8.1 Introduction
It has been proposed that Helicobacter pylori 
possesses abundant urease activity in order to survive low 
intragastric pH (181-183). It has been suggested that the 
urease activity might create an alkaline microenvironment 
around it and thereby neutralise gastric acidity which 
would otherwise destroy the organism. The previous 
studies of gastric juice urea concentrations and the 
effects of urea infusion have shown that when the organism 
colonises the gastric antral mucosa ammonium production by 
its urease activity is limited by the availability of urea
(243). Direct alkalinisation of the gastric antrum by the 
infusion of a buffer solution results in an increased 
plasma gastrin concentration but stimulation or inhibition 
of ammonium production to alter any urease produced 
alkaline microenvironment did not change basal or meal 
stimulated gastrin responses (243-245). These studies 
demonstrated that H pylori does not produce an 
alkalinisation of its immediate in vivo environment 
sufficient to alter plasma gastrin concentrations.
Although these in vivo studies suggest that urease 
activity may not be necessary for the survival
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of H pylori in the stomach some in vitro studies have 
shown that urease activity protects the bacterium from low 
pH (183-185).
If the function of the organism's urease activity is 
to protect it from acidity then it might be expected that 
increased urease activity and ammonium production would 
occur when the pH of the medium around the organism was 
reduced. The survival of the organism, its utilisation of 
urea and production of ammonium were therefore 
investigated in a series of in vitro studies using buffer 
solutions ranging from pH 1.5 to 7.0. The effects 
increasing urea concentration and inhibition of urease 
activity with hydroxyurea were also examined.
8.2 Methods
The survival of H pylori at a range of buffer pH was 
investigated. The effect of varying the initial urea 
concentration in the buffer and of adding the urease 
inhibitor hydroxyurea was studied. In each experiment 1 
ml of a 72 hour broth culture suspension (BHI broth +
0.25% yeast extract + 10% horse serum) of H pylori was 
added to 9 ml of 0.2 mol/L citrate buffers or to isomolar 
unbuffered saline and incubated at 37°C. At intervals 
portions were removed for viable bacterial counts and 
where appropriate for measurement of ammonium (Enzymatic 
method Cobas Bio) and urea (o-pthalaldehyde method 
Perspective analyser) concentrations. The pH was
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monitored using a combined glass electrode (Radiometer GK
2802C).
Using the above protocol the following studies were 
undertaken:
1. The survival of the organism with 50 mmol/L urea 
at varying pH
The survival of the organism was studied in 0.2 mol/L 
citrate buffer in the presence of 50 mmol/L urea at pH 
1.5,2.0,3.0,4.0,5.0,6.0 and 7.0 during a 60 minute 
incubation.
2. The survival of the organism at pH 6.0 during a 5 min 
incubation with 10 mmol/L urea
The survival of the organism during a 5 minute 
incubation was compared in citrate buffer pH 6.0 and 
isomolar unbuffered saline both with and without 10 mmol/L 
urea.
3. The effect of increasing urea concentration 
on survival at pH 6.0
The effect of varying the starting concentration of 
urea on survival at pH 6.0 in citrate buffer was assessed.
4. The effect of the addition of hydroxyurea on survival 
at pH 6.0 in the presence of urea
The effect of adding the competitive urease 
inhibitor, hydroxyurea on the survival of H pylori at pH
6.0 in the presence of 10 mmol/L urea was examined.
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5. The effect of the addition of hydroxyurea on survival
at pH 3.0 in the presence of urea.
The effect of adding the competitive urease inhibitor 
hydroxyurea on the survival of H pylori at pH 3.0 in the 
presence of 10 mmol/L urea was also examined.
A microtitre modification of the method of Miles and 
Misra (220) was used to establish survival. The portions 
removed for biochemical analysis were immediately filtered 
to remove the organism (Gelman Sciences, Acrodisc 0.2 um) 
and stored at -20°C. Experiments were performed with 
both NCTC 11637 culture of H pylori and with fresh 
clinical isolates. Statistical analysis was performed 
using the Mann-Whitney U test.
8.3 Results
The starting inoculum was determined separately for 
each experiment and was consistently 105-6 cfu/ml. The 
pH of the incubating solution remained constant in each of 
the experiments employing citrate buffer. In the saline 
experiments, the pH at the start ranged from 6.26-6.60 and
at 5 minutes had risen to pH 7.04-7.50.
1 The survival of the organism with 50 mmol/L urea at
varying pH
At pH 1.5 the survival of the organism was impaired 
although the buffer contained 50 mmol/L urea (Table 8.1).
As the pH increased the survival of the organism improved
until pH 5.0 and 6.0 were reached when little or no
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Table 8.1
Median % survival at a range of pH 
in the presence of 50 mmol/L urea
Time pH 1.5 pH 2.0 pH 3.0 pH 4.0 pH 5.0 pH 6.0 pH 7.0
10 min 0 4.9 17.6 65.6 1.2 1.9 71.6
30 min 5.1 51.1 112.0 56.3 0.3 0 85.0
60 min 9.1 89.9 55.0 50.3 0.1 0 91.3
The median percentage of initial inoculum of H pylori surviving 
in 0.2 mol/L citrate buffer with 50 mmol/L urea at a range of 
pH from 1.5 to 7.0.
survival of the organism was found following an incubation 
of only 10 minutes. When the pH of the buffer was 
increased to pH 7.0 survival of the bacterium returned to 
close to 100% of the initial inoculum These experiments 
were conducted using isolate 788 of the organism.
2 The survival of the organism at pH 6.0 during a 
5 minute incubation with 10 mmol/L urea
The median 5 minute survival in citrate buffer pH 6.0 
was reduced when only 10 mmol/L urea was present in the 
incubation medium, 26%, (range 0-87%) with urea, compared 
with 96%, (range 28-179%) without urea, (pcO.OOl).
Similar results were obtained when fresh clinical isolates 
H pylori were also tested confirming that this was not 
solely a feature of the NCTC 11637 strain.
The median 5 minute survival in isomolar saline was 
not affected by the addition of 10 mmol/L urea (81% 
without urea compared with 77% with urea). The saline 
experiments were allowed to run for up to 2.5 hours with 
no difference in survival.
3 The effect of increasing urea concentration 
on survival at pH 6.0
The mean 5 minute survival at pH 6.0 decreased with 
increasing concentration of urea from 121% (range 69-148) 
in the absence of urea to only 9%, (range 0-22) with 50 
mmol/L urea (Fig 8.1).
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4 The effect of the addition of hydroxyurea on survival
at pH 6.0 in the presence of urea
The addition of hydroxyurea inhibited the killing 
effect at pH 6.0. The protective effect increased with 
increasing concentration of hydroxyurea (Fig 8.2). The 
median 5 min ammonium concentration at pH 6.0 in the 
presence of 10 mmol/L urea was 2.5 mmol/L (range 1.9-7.6) 
compared with 1.13 mmol/L (range 0.8-1.3) in the blank 
incubation. When 10 mmol/L hydroxyurea was added the 
median 5 minute ammonium concentration was reduced to 1.29 
mmol/L (range I .03-1.53)(p<0.001) indicating effective 
inhibition of the enzyme.
5 The effect of hydroxyurea on survival
at pH 3.0 in the presence of urea
The addition of hydroxyurea in the presence of urea 
at pH 3.0 reduced the survival of the organism. The 
median 5 min survival of the organism in 0.2 mol/L citrate 
buffer pH 3.0 was 0% (range 0-2) compared with 179% (range 
86-197) in the presence of 10 mmol/L urea (p<0.05). The 
median 5 min survival in the presence of 10 mmol/L urea 
and 100 mmol/L hydroxyurea was reduced, 15% (range 0-64%), 
compared with survival in citrate buffer containing 10 
mmol/L urea (p<0.05). The median final ammonium 
concentration in the buffer was greater in the presence of 
urea alone (1.30 mmol/L, range 1.19-1.36) compared with 
the presence of both urea and hydroxyurea (1.15 mmol/L, 
range 1.12-1.16) indicating inhibition of urease activity.
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H pylori in citrate buffer pH 6 plus 10 mmol/L urea.
8.4 Discussion
The rapid death of H pylori can be induced in vitro 
by altering both the pH and urea concentration of the 
organism's environment. Paradoxically urea protects the 
organism from the lethal effects of exposure to a pH of
4.0 or less and causes the organism's destruction at pH
5.0 and 6.0. Similarly the addition of the urease 
inhibitor hydroxyurea to the incubate results in the 
destruction of the organism at pH 3.0 and its survival at 
pH 6.0 despite the presence of urea. The rapid death of 
H pylori without the use of conventional antibacterial 
agents indicates that its destruction may be the 
consequence of the metabolic effects of uncontrolled 
urease activity. The use of isomolar saline, and citrate 
buffers without any urea added shows that the effect is 
not merely a result of altered osmolality of the 
environment. The protection of H pylori from destruction 
at pH 6.0 in the presence of urea by the addition of the 
specific urease inhibitor hydroxyurea suggests that its 
destruction is a result of over-production of ammonium 
resulting in irreversible metabolic damage. The activity 
of the urease enzyme is not suppressed by ammonium as a 
result of the absence of a protective feedback control 
mechanism (191).
Although the addition of urea protected the organism 
from pH 3.0 it did not alter the buffer pH or produce 
large quantities of ammonium which could create an
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alkaline microenvironment. Inhibition of urease activity 
by hydroxyurea was fatal at low pH although buffer 
ammonium concentrations were only slightly reduced. This 
suggested that intracellular neutralisation of acidity by 
the production of ammonium might be more important for 
survival at low pH than the creation of an extracellular 
alkaline microenvironment.
Whether it will be possible to induce the destruction 
of H pylori in vivo by altering the pH and urea 
concentration of the gastric contents remains to be seen. 
Ammonium production can be increased by the infusion of 
urea (243). The pH of gastric juice can be altered by 
treatment with acid inhibitory agents. Patients with 
increased gastric pH due to pernicious anaemia or due to 
duodenogastric alkaline reflux following gastric surgery 
have a low prevalence of H pylori infection (113,246). In 
addition treatment with the powerful acid inhibitory agent 
omeprazole which raises intragastric pH to near neutral 
values has been reported to clear H pylori infection by 
some investigators (204,205). Omeprazole does not have 
any direct toxic or inhibitory effect on H pylori in vitro 
(208). It is also of interest that patients with uraemia 
have a lower prevalence of H pylori (247,248).
These studies might indicate a potential new approach 
to the treatment of H pylori infection. The mechanism of 
its urease mediated destruction deserves further 
investigation.
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UREASE MEDIATED DESTRUCTION OF HELICOBACTER PYLORI IS
DUE TO INTRACELLULAR ACCUMULATION OF AMMONIUM
9.1 Introduction
In the previous in vitro studies the paradoxical 
effects of urease activity on the survival of H pylori in 
citrate buffer were discovered. High concentrations of 
urea while protecting the organism in acid buffer at pH
3.0 caused its destruction at pH 6.0. Administration of 
the specific urease inhibitor hydroxyurea in the presence 
of urea resulted in the destruction of the organism at low 
pH and its survival at pH 6.0, thereby demonstrating that 
the survival of the organism at low pH and its destruction 
at pH 6.0 were mediated by its urease activity. The speed 
of death in citrate buffer pH 6.0 with a urea 
concentration of 50 mmol/L suggested that this was the 
result of a catastrophic metabolic failure. The reduction 
in colony forming units of the bacterium following a 5 
minute incubation in citrate buffer with urea was greater 
than which could be produced with microaerophilic 
Campylobacters during a 2 hour in vitro incubation with 
metronidazole (249). The speed and extent of the 
destruction of the organism suggested that if it could be 
harnessed in vivo it could provide a new therapeutic 
approach for the treatment of duodenal ulcers. In order
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to investigate the biochemical basis of the suicidal 
process the organism's urea metabolism in environments 
causing its rapid death has been compared with that in 
environments in which it survived.
9.2 Methods
The earlier studies had indicated that pH, urea 
concentration and type of buffer may have contributed to 
the metabolic destruction of the organism. The effect of 
each of these on the organism's urea metabolism and 
survival was examined. The effect of adding metabolic 
intermediates used in intracellular ammonium metabolism 
was also examined.
1. The effect of pH
The survival of the organism its urea consumption and 
ammonium release in 0.2 mol/L citrate buffer pH 6.0 
containing 50 mmol/L urea were compared with that in the 
same solution at pH 7.0. Similar studies were also 
conducted with unbuffered isomolar saline at pH 6.0 
containing 50 mmol/L urea and 0.2 mol/L citrate buffer pH
6.0 without urea.
2. The effect of urea concentration
The effect of increasing the initial urea 
concentration on urea consumption, ammonium release and 
survival of the organism in 0.2 mol/L citrate buffer pH
6.0 was investigated. The following urea concentrations 
were examined:- 1 mmol/L, 5 mmol/L, 10 mmol/L, 20 mmol/L, 
30 mmol/L and 50 mmol/L.
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3. The effect of buffer ammonium ion concentration
The effect of the addition of 10 mmol/L ammonium 
chloride to 0.2 mol/L citrate buffer pH 6.0 on the 
survival of the organism was investigated.
4. The effect of citrate buffer
The survival of the organism in the presence of 30 
mmol/L urea in 0.2 mol/L citrate buffer pH 6.0 was 
compared with survival in 0.2 mol/L acetate buffer pH 6.0 
containing 30 mmol/L urea, and with 0.2 mol/L phosphate 
buffer pH 6.0 also containing 30 mmol/L urea. Urea 
consumption and percentage ammonium released were also 
measured.
5. The effect of isocitric acid buffer
The survival of the organism in the presence of 50 
mmol/L urea in 0.2 mol/L isocitrate buffer pH 6.0 was 
compared with its survival in 0.2 mol/L citrate buffer 
with the same concentrations of urea.
6. The effect of the addition of alpha ketoglutarate 
The survival of the organism following a 3 day pre­
incubation in broth with 10 mmol/L alpha ketoglutarate, 
and then during a subsequent 5 min incubation in 0.2 mol/L 
citrate buffer pH 6.0 with a urea concentration of 50 
mmol/L was compared with its survival in the buffer with 
urea but without pre-incubation with alpha ketoglutarate.
7. The recovery of urea and ammonium in citrate buffer 
in the absence of the organism.
The recovery of ammonium and loss of urea from the 
experimental system was investigated by incubating 1, 5
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and 10 units of Jackbean urease enzyme (Sigma Chemical 
Company, Dorset, UK) in 5 ml of 0.2 mol/L citrate buffer 
pH 6.0 with 50 mmol/L urea at in a waterbath for 10
min. Following the incubation the enzymatic reaction was 
stopped by the addition of 2 ml of 1 mol/L HC1 which 
reduced the pH of the buffer to 3.0. Samples were stored 
frozen at -20~C until analysis. The urea and ammonium 
concentrations in these samples were measured as 
previously described.
8. Removal of urease activity by filtration of samples
The urease activity in the filtered samples was
measured by the urease method previously described.
The method G f  Miles and Misra (220) was used to 
establish survival of the organism. The 1 ml sample 
collected for urea and ammonium analyses was filtered 
(Gelman Sciences, Acrodisc 0.2 urn) to remove the organism, 
snap frozen and stored at -20°C until analysis. The
urea concentration was measured by the o-pthalaldehyde
method and the ammonium concentration using the enzymatic 
method described for the Cobas Bio.
The stock buffer solutions used were 0.2 mol/L sodium 
citrate buffer pH 6.0 and pH 7.0, 0.2 mol/L sodium 
isocitrate buffer pH 6.0, 0.2 mol/L sodium acetate buffer 
pH 6.0 and 0.2 mol/L sodium phosphate buffer pH 6.0. 
Isomolar sodium chloride solution was adjusted to pH 6.0 
prior to use. To obtain a range of urea concentrations,
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stock solutions with urea concentrations of 0.1 mol/L, 0.5 
mol/L, 1 mol/L, 2 mol/L, 3 mol/L and 5 mol/L were made.
All the stock solutions were stored at -20°C until use.
To set the initial urea concentration in the buffer 100 ul 
of the appropriate stock urea solution was added to 8.9 ml 
of the required buffer, to give final urea concentrations 
of 1 mmol/L, 5 mmol/L, 10 mmol/L, 20 mmol/L, 30 mmol/L, or 
50 mmol/L in the final suspension. Buffers were 
equilibrated at 37c>C and their pH checked prior to each 
experiment. To commence each experiment 1 ml of a 72 h 
broth culture suspension was added to 9 ml of buffer as 
previously described.
9.4 Results 
1 The effect of pH
The median 5 min survival of H pylori when incubated 
at 37°C in 0.2 mol/L sodium citrate buffer pH 6.0, with 
an initial urea concentration of 50 mmol/L was only 14% 
(range 0-22%) compared with 53% (range 31-112) when 
incubated in the same solution but at pH 7.0 (p<0.01) (Fig 
9.1). The organism's survival in citrate buffer at pH 6.0 
with 50 mmol/L urea was also reduced in comparison with 
survival in isomolar saline containing 50 mmol/L urea, 
(median 65%, range 29-113%) (p<0.01) and with survival in 
0.2 mol/L sodium citate buffer pH 6.0 without any added 
urea (median 60%, range 33-114%) (p<0.01)(Fig 9.1).
Urea utilization was similar in pH 6.0 buffer and in 
pH 7.0 buffer, being 154 umol/5 min (126-162) and 162
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containing 50 mmol/L urea, and 0.2mol/L citrate buffer pH 7.0 
containing 50 mmol/L urea.
umol/5 min (73-188) respectively (Table 9.1). The median 
amount of ammonium found at 5 min in the incubate at pH
7.0 was 18 umol, (range 8-21) which was significantly 
greater than at pH 6.0, 9 umol, (range 7-10) (p<0.01)
(Table 9.1).
2 The Effect of Urea Concentration
The median 5 min survival of the organism in 0.2 
mol/L citrate buffer pH 6.0 progressively fell with 
increasing initial urea concentrations from 89% (range 
19-124%) at 1 mmol/L to 39% (range 13-87%) at 10 mmol/L, 
29% (range 10-64%) at 30 mmol/L and to 14% (range 0-22%) 
at 50 mmol/L. Although the median percentage survival of 
the organism fell as the initial urea concentration 
increased, the amount of urea used by the organism during 
the 5 min incubation increased from 9 umol (range 7 - 9 )  
at an initial urea concentration of 1 mmol/L to 32 umol 
(range 14-92 umol) at 10 mmol/L (p<0.05), 98 umol (range 
15-281 umol) at 30 mmol/L (p<0.01), and 146 umol (range 11 
- 171) at an initial urea concentration of 50 mmol/L 
(p<0.01) (Fig 9.2). The percentage recovery of ammonium 
from the hydrolysis of urea fell as the initial urea 
concentration increased (Fig 9.3). With an initial urea 
concentration of 1 mmol/L, the median 5 min recovery of 
ammonium was 27% (range 7-94%) compared with 18% (range 
15-80%) at 10 mmol/L, 16% (range 4-315%) at 30 mmol/L, and 
only 3% (2-22%) at 50 mmol/L urea (p<0.01 versus 1 mmol/L 
urea).
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Buffer Urea hydrolysed 
umol/5 min 
median 
(range)
NH4 +
produced 
umol/5 min 
(range)
Table 9.1 
% Survival 
median 
(range)
Citrate 154
pH 6.0 (126-162)
50 mmol/L urea 
n~8
Citrate 162
pH 7.0 (73-188)
50 mmol/L urea 
n=8
Isomolar saline 200 
pH 6.0 (182-225)
50 mmol/L urea 
n=8
Citrate
no urea pH 6.0
n=8
* p<0.01
o *
(7-10)
18
(8-21)
10
)
14 * 
(0-22)
53
(31-112)
65
(29-113)
60
(33-114)
Survival, urea utilisation and ammonium production 
in 0.2 mol/L citrate buffer pH 6.0 and pH 7.0.
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ammonia expected to have been formed as a result of hydrolysis of 
urea by H pylori in 0.2mol/L citrate buffer pH 6.0 with initial urea 
concentrations from 1 to 50 mmol/L. For urea concentrations of 1 to 
20 mmol/L, n-1  and for 30 mmol/L urea n=17 and for 50 mmol/L urea 
n=9.
3 The Effect of Buffer Ammonium Ion Concentration
The survival of the organism in 0.2 mol/L citrate 
buffer pH 6.0 in the presence of 10 mmol/L ammonium 
chloride was investigated. The median ammonium 
concentration of the 12 replicate experiments when 
measured at the start was 10.7 mmol/L (range 9.7-13.1) and 
at the end it was 10.9 mmol/L (range 10.6-11.3). The 5 
min survival of the organism in buffer with ammonium 
chloride, (median 64%, range 20-137%) was similar to its 
survival in 0.2 mol/L sodium citrate buffer pH 6.0, 
without any additions (median 60%, range 33-148%).
4. The Effect of Citrate Buffer
The median 5 min survival in buffer pH 6.0 in the 
presence of 30 mmol/L urea when citrate buffer was used 
was 29% (range 10-64%) compared with 80% (range 26-160%) 
when acetate buffer was used (p<0.01) (Table 9.2). The 
amount of urea used by the organism in the acetate buffer, 
(median 215 umol, range 18 - 272) was not statistically 
different from that in the citrate buffer, (median 97 umol 
range 5-282). The median 5 min ammonium concentration was 
similar in the acetate buffer, (33 umol, range 7-132) to 
that in the citrate buffer (19 umol, range 7-41). The 
percentage of ammonium recovered from the hydrolysis of 
urea in the acetate buffer (12.1%) was also similar to 
that (8.6%) in the citrate buffer. In the absence of urea 
the 5 min survival in citrate buffer pH 6.0 was still 
reduced (68%, range 33 - 163%) when compared with survival 
in the acetate buffer pH 6.0 (95%, range 36 - 211%)
(p < 0 .05).
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Table 9.2
suffer Urea NH^-" % recovery
hydrolyzed produced of NR-*-"
umol/5 min umol/5 min median
median median (range)
(range) (range)
Citrate 
buffer 
pH 6.0 with 
30 mmol/L 
urea 
n=18
97
(5-282)
19
(7-41)
8.6%
(2.6-61)
Acetate
buffer
pH 6.0 with
30 mmol/L
urea
n=18
215
(18-272)
33
(7-132)
12.1%
(3.5-90)
*p<0.01
% survival 
median 
(range)
29*
(10-64)
80
(26-160)
Survival, urea utilisation and ammonium production in 0.2 
mol/L citrate buffer compared with 0.2 mol/L acetate buffer.
The median 5 min survival of H pylori in the presence 
of 30 mmol/L urea in phosphate buffer, at pH 6.0 (100%, 
range 72-128) was also greater than that in citrate buffer 
(42%, range 27-55) (p<0.05) (Table 9.3). In the absence 
of urea survival was similar in citrate (83% range, 
75-103%) and phosphate buffers (90%, range 82-126%). A 
similar amount of urea was consumed in the phosphate 
buffer, (83 umol, range 0-296) and in the citrate buffer, 
(120 umol, range 19-264). The median percentage recovery 
of ammonium from urea hydrolysed was again similar for 
both buffers, 17% for citrate and 15% for phosphate (Table 
9.3) .
5 The Effect of Isocitric Acid buffer
The median 5 min survival of the organism in 0.2 
mol/L isocitrate buffer containing 50 mmol/L urea was 37% 
(range 0-274%), compared with 9.9% (range 0-146%) in 0.2 
mol/L citrate buffer with 50 mmol/L urea (Table 9.4) 
(p<0.01). The utilisation of urea was similar in the 
isocitrate buffer, median 3.9 mmol/L (range 0-24) to that 
in the citrate buffer median 3.8 mmol/L (range 0-28)
(Table 9.5). There was no significant difference in 
ammonium production between the two buffers. The median 
final ammonium concentration in the isocitrate buffer was 
similar, 5.34 mmol/L (range 1.83-27.6) compared with 4.24 
mmol/L (range 2.11-27.1) in citrate buffer (Table 9.5).
6 The Effect of the addition of Alpha Ketoglutarate
The median 5 min survival of the organism in 0.2
mol/L citrate buffer containing 50 mmol/L urea following a
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Table 9.3
Buffer Urea NK4- % recovery
hydrolyzed produced of NH4'“
umol/5 min umol/5 min median
median median (range)
(range} (range)
C 1 1 r ate
buffer
pH 6.0 with
3 0 iiuno 1 / L
urea
n=7
120
(19-264)
39
(32-41)
17%
(7.4-21)
Phosphate
buffer
pH 6.0 with
30 mmol/L
urea
n=7
83
(0-296)
30
(5-36)
15%
(4.3-19%)
*p<0.05
% survival 
median 
(range)
42 * 
(27-55%)
100
(72-128)
Survival, urea utilisation and ammonium production 
in 0.2 mol/L citrate buffer compared with 0.2 mol/L 
phosphate buffer.
Table 9
Survival of H pylori 
% of initial inoculum
Buffer median range
Citrate buffer pH 6.0 88 18-384
Isocitrate buffer pH 6.0 88 15-274
Citrate buffer pH 6.0
+ 50 mmol/L urea 9.9* 0-164
Isocitrate buffer pH 6.0
+ 50 mmol/L urea 37 0-274
* p <0.01 vs isocitrate buffer with urea
Survival in 0.2 mol/L citrate buffer pH 6.0 compared 
0.2 mol/L isocitrate buffer pH 6.0.
Table 9.5
Decrease m  
Urea
concentration 
mmol/L 
(range)
Final
Ammonium
concentration
mmol/L
(range)
citrate buffer 
+ 50 mmol/L urea 3.8
(0-28.0)
* 4.24 
(2.11-27.1)
isocitrate buffer 
+ 50 mmol/L urea 3.9 
(0-24.0)
* 5.34 
(1.83-27.6)
p >0.5 : NS
Urea utilisation and ammonium production in 0.2 mol/L 
citrate buffer pH 6.0 with 50 mmol/L urea compared
with 0.2 mol/L isocitrate buffer pH 6.0.
72h pre-incubation with 10 mmol/L alpha ketoglutarate, was 
greater, (43%, range 3 - 256%), than its survival in 0.2 
mol/L citrate buffer with the urea but without 
pre-incubation with alpha ketoglutarate, (14%, range
0-22%)(p<0.01).
Following pre-incubation with alpha ketoglutarate the 
median 5 min survival in the citrate buffer pH 6.0 
containing the urea (43%, range 3-256%), was similar to 
the organism's 5 min survival in the pH 6.0 citrate buffer 
but without urea (70%, range 3-323%) (p>0.5 N S ).
7 The recovery of urea and ammonium in citrate 
buffer in the absence of the organism 
Following a 10 min incubation the recovery of
ammonium in citrate buffer containing 50 mmol/L urea was 
proportional to the amount of urease enzyme added. When 1 
unit of enzyme was added the mean (+ SD) 10 minute 
ammonium concentration was 5.6 mmol/L (+_ 0.62) with 5 
units of enzyme it was 21.0 mmol/L (+_ 2.4) and when 10 
units of enzyme were added the 10 minute ammonium 
concentration was 46.2 mmol/L (+_ 4.40). The amount of 
urea hydrolysed by the enzyme was accounted for by the 
production of ammonium. The mean urea consumed was 2.7 
mmol/L with 1 unit of urease, 12 mmol/L with 5 units of 
enzyme and 22.9 mmol/L with 10 units of enzyme, giving 
recoveries of 103%, 91% and 101% respectively.
8 Urease activity in filtered samples
Urease activity was not detected in the filtered 
samples when checked prior to urea and ammonium 
measurement.
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9.5 Discussion
The rapid destruction of H pylori in citrate buffer 
was due to a combination of the pH of the solution, urea 
concentration and citrate. The speed of the bacterium's 
destruction indicated that the effect was mediated through 
its metabolism.
The importance of the pH of the citrate buffer was 
demonstrated by the organism's improved survival in 
citrate buffer solution pH 7.0 containing 50 mmol/L urea 
compared with its survival in the same solution at pH 
6.0. Although similar amounts of urea were utilised less 
ammonium was released into the incubate at pH 6.0 than at 
pH 7.0. This might explain the organism's impaired 
survival at pH 6.0 in the presence of urea.
The survival of H pylori also decreased with 
increasing initial urea concentration in pH 6.0 citrate 
buffer again indicating that the suicidal destruction was 
linked to urease activity. This observation was 
consistent with the finding from the initial in vitro 
studies that the urease inhibitor hydroxyurea enhanced the 
survival of the organism in citrate buffer pH 6.0. The 
percentage recovery of the ammonium fell with increasing 
initial urea concentration. This indicated that the 
organism may have been unable to excrete the ammonium 
generated by urea hydrolysis as rapidly as it was 
produced. This failure to excrete ammonium may explain 
its rapid death.
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The addition of 10 mmol/L ammonium to the citrate 
buffer solution did not reduce the survival of the 
organism which indicated that it was the production of 
ammonium by urease activity and the effects of the 
ammonium within the cell which proved harmful to the 
organism.
Citrate was also necessary for the bacterium's 
destruction as the organism survived well in phosphate and 
acetate buffers containing the same concentration of 
urea. The percentage recovery of ammonium was similar in 
acetate and phosphate buffers to that in citrate buffer. 
The contribution of citrate to the destruction of the 
organism cannot be explained by alteration of urease 
activity or ammonium excretion.
If ammonium produced by urease activity entered the 
cell then it could be used in the formation of glutamate 
or glutamine by glutamate dehydrogenase and glutamine 
synthetase respectively. Both of these reactions consume 
high energy intermediates but glutamate dehydrogenase also 
uses alpha ketoglutarate to form glutamate. Alpha 
ketoglutarate is a key intracellular metabolite which 
links carbon metabolism with nitrogen metabolism (Fig 
9.4). It is possible that citrate when present in high 
concentrations could inhibit the activity of the enzyme 
isocitrate dehydrogenase (250). Isocitrate differs from 
citrate only by the transposition of the hydroxyl group 
from the central carbon atom of the molecule to one of the 
adjacent carbon atoms (Fig 9.5). Isocitrate dehydrogenase
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catalyses one of the key steps involved in the generation 
of alpha ketoglutarate from citrate (Fig 9.6). The 
simultaneous inhibition of synthesis of alpha 
ketoglutarate by citrate and stimulation of its 
utilisation by urease activity could result in the 
complete depletion of this compound in the bacterium with 
intracellular accumulation of ammonium and a rise in 
intracellular pH.
The survival of H pylori in the isocitrate buffer pH
6.0 with 50 mmol/L urea was greater than in citrate buffer 
pH 6.0 containing the same concentration of urea. This 
was consistent with the hypothesis that the depletion of 
intracellular alpha ketoglutarate resulted in the 
destruction of the organism. The absence of any 
difference in recovery of ammonium or urea consumption 
over the 5 minutes of the experiment between the 
isocitrate and citrate buffers was consistent with 
protection of the organism by the production of more 
intracellular alpha ketoglutarate which reduced 
intracellular ammonium concentrations.
The protective effect of 0.2 mol/L isocitrate buffer 
was less effective than the destructive effect of citric 
acid. This may be due to other metabolic factors such as 
a greater rate of production of ammonium by the organism's 
abundant urease activity than the rate of production of 
alpha ketoglutarate by isocitrate dehydrogenase. In 
addition the isocitric acid used was a racaemic mixture 
and only the L stereoisomer would be biologically active
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(Fig 9.5). As a result a 0.2 mol/L solution of isocitric 
acid could be less biochemically effective than the same 
concentration of the citrate buffer.
The hypothesis that intracellular depletion of alpha 
ketoglutarate leads to the intracellular accumulation of 
ammonium and thereby results in the bacterium's 
destruction was also supported by the observation that 
pre-incubation of the organism with alpha ketoglutarate 
protected it from the lethal effects of citrate buffer at 
pH 6.0 containing urea.
The almost complete recovery of ammonium produced 
when Jackbean urease enzyme was added to citrate buffer 
with 50 mmol/L urea demonstrated that the ammonium lost 
from the experimental system was not blown off during the 
experiment or lost on the plastic containers, or glassware 
or during storage. The ammonium not recovered must have 
accumulated within the bacterium which was removed by 
filtration prior to urea and ammonium analysis.
Failure to detect urease activity in the filtered 
samples also indicated that any loss of urea prior to 
analysis did not occur as a result of residual urease 
activity not removed by filtration.
The location of the urease enzyme is thought to be on 
the exterior surface of the organism's periplasmic 
membrane (201, 202). Uncontrolled production of ammonium 
by the urease activity at localised sites could lead to 
the rapid accumulation of high concentrations of ammonium
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just outside the cell. Intracellular ammonia 
concentrations are low and it is therefore possible that 
ammonia produced by urease activity could diffuse down the 
concentration gradient into the cell almost as rapidly as 
it was produced. Once the ammonia had been protonated 
within the cell the resultant ammonium ions would be 
unable to re-cross the cell membrane and diffuse out of 
the cell as easily. This would explain why high 
concentrations of extracellular ammonium ions which were 
not able to cross the cell membrane easily were not 
harmful to the organism and also how utilisation of small 
quantities of urea at low pH could enhance the survival of 
the bacterium through the neutralisation of intracellular 
acid.
H pylori is difficult to eradicate with conventional 
treatment. Even triple therapy with tripotassium 
dicitrato bisthmuthate, metronidazole, plus either 
amoxycillin or tetracycline for 2-4 weeks fails to 
eradicate the infection in 10-20% of patients (218). The 
development of antibiotic resistance is also proving a 
problem (219). These in vitro observations may indicate 
the biochemical basis of a potential new approach to 
killing the organism in vivo. The in vivo urea 
experiments have already demonstrated that ammonium 
production by the organism can be stimulated in the human 
stomach (243), thereby raising the possibility that the in 
vitro conditions could be reproduced in patients.
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In conclusion, H pylori rapidly dies in citrate 
buffer pH 6.0 containing urea. This is due to the 
metabolic consequences of the rapid intracellular 
accumulation of ammonium.
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CHAPTER 10
FINAL DISCUSSION AND CONCLUSIONS
FINAL DISCUSSION AND CONCLUSIONS
10.1 The detection of Helicobacter pylori infection
Infection of the gastric antral mucosa by 
Helicobacter pylori results in low gastric juice urea 
concentrations and raised gastric juice ammonium 
concentrations. Standard enzymatic and chemical 
analytical methods may be used to measure these changes in 
concentration. The ratio of gastric juice urea to 
ammonium concentrations is characteristically less than 
0.8 when the infection is present and greater than 0.9 
when infection is absent. Calculation of this ratio may 
be used to detect infection with H pylori as reliably as 
using the 14C-urea breath test. The ratio was 
unaffected by high plasma and gastric juice urea 
concentrations found in renal failure and was also not 
altered by the administration of H?.. receptor antagonists 
such as ranitidine. This test has the further advantage 
that delay in analysis should not affect the 
discriminating ability of the ratio as any urease activity 
in a stored sample could only cause a further reduction of 
urea concentration and resulting increase in ammonium 
concentration, which would only ensure that the ratio 
remained within the range found in H pylori positive 
individuals. An additional advantage of this test for the
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detection of infection is that it may be possible to 
analyse the gastric juice samples in the endoscopy suite 
using some of the currently available bedside biochemistry 
analysers. The Kodak Ektachem system (Kodak, Herts, UK) 
which could be suitable for endoscopy suite measurement of 
ammonium concentrations, has already been used 
successfully to measure gastric juice ammonium 
concentrations (251).
The disadvantage of the test was that fasting gastric 
juice samples needed to be collected.
When simple and reliable methods of eradicating the 
infection are developed then the importance of 
establishing the presence of infection for the clinical 
management of patients with duodenal ulcers will 
increase. The measurement of the urea/ammonium ratio in 
gastric juice could prove a useful test as it is unlikely 
that arrangements for 14C-urea breath tests would be 
readily available for the investigation of patients 
attending District General Hospitals. Histological 
examination of biopsies and the culture of the organism 
v/ill be widely available but are more labour intensive, 
and less easily automated than biochemical analysis. In 
addition, once a widely usable effective treatment for the 
organism becomes available the number of patients 
requiring determination of H pylori status may exceed the 
capacity of the standard histological and microbiological 
techniques. The only other easily automated and 
relatively simple method of investigating infection is by
126
serology which has not currently gained wide acceptance 
and has proved to be unreliable in older age groups
(80-85).
10.2 Ammonium production by Helicobacter pylori 
and its effect on gastrin release in vivo 
The in vivo studies demonstrated that Helicobacter 
pylori urease activity in subjects with chronic infection 
and duodenal ulcer disease is usually limited by substrate 
availability (243). Ammonium production could be 
stimulated by the infusion of urea containing solutions 
and gastric juice urea concentrations also rose rapidly in 
response to inhibition of urease activity by 
acetohydroxamic acid.
While ammonium production by the organism's urease 
activity could be altered these studies also showed that 
raised plasma gastrin concentrations in individuals with 
the infection were not due to the organism's urease 
activity. Stimulation of urease activity by urea 
infusion, and inhibition of urease activity with 
acetohydroxamic acid did not alter the basal plasma 
gastrin concentration or the meal stimulated gastrin 
response either before or after eradication of the 
organism.
Prolonged alkalinisation of the gastric antrum by the 
infusion of citrate buffer pH 7.0 did cause an increase in 
plasma gastrin concentration and meal stimulated gastrin 
response but a significant difference between H pylori 
positive and negative subjects was not demonstrated 
(245) .
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As direct alkalinisation of the gastric antrum caused 
increased gastrin release while stimulation and inhibition 
of urease activity did not alter plasma gastrin 
concentration it is unlikely that the organism's urease 
activity created a significant alkaline microenvironment 
in the neighbourhood of the gastric epithelial cells in 
the antrum. Other explanations for the purpose of the 
abundant urease activity of this micro-organism were 
therefore examined.
10.3 The effect of pH and urea on survival of 
Helicobacter pylori in vitro
Urease activity was shown to enhance the in vitro
survival of Helicobacter pylori at pH 3.0. The addition 
of the urease inhibitor hydroxyurea abolished the 
protective effect of urea at low pH confirming that 
enhanced survival was due to urease activity. Although 
urease activity enhanced survival at low pH only small 
quantities of ammonium were produced which were 
insufficient to alter the pH of the buffer. This 
suggested that intracellular buffering of pH may be of 
more importance than the creation of an alkaline
microenvironment for the survival of the micro-organism.
Urease activity may therefore be of importance in the 
survival of the organism during its initial passage 
through the gastric juice at the time the infection is 
acquired.
While urea enhanced survival of the organism in 
citrate buffer at pH of 3.0 it was also associated with
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the rapid destruction of the organism at pH 5.0 and 6.0.
H pylori could be protected from the destructive effects 
of incubation in citrate buffer pH 6.0 with urea by the 
addition of the urease inhibitor hydroxyurea. In 
addition, when the initial urea concentration in the 
citrate buffer at pH 6.0 was increased from 1 to 50 mmol/L 
an almost dose dependent reduction in survival occurred. 
These observations demonstrated that urease activity 
caused the in vitro destruction of the organism at pH 6.0.
Citrate buffer itself was required for the 
destruction of the organism through its urease activity. 
The organism survived lethal urea concentrations in 
phosphate and acetate buffers at pH 6.0.
The survival of the organism in citrate buffer pH 6.0 
containing 10 mmol/L ammonium chloride, the reduction in 
recovery of ammonium as the initial buffer urea 
concentration was increased and the increased survival of 
the organism at pH 7.0 which was associated with increased 
recovery of ammonium all indicated that intracellular 
metabolism of ammonium produced by urease activity was 
required for the destruction of H pylori.
It is unlikely that the low recovery of ammonium in 
the in vitro studies was due to loss from the experimental 
system. Prolonging the incubation of the organism in 
citrate buffer pH 6.0 up to 2 h produced almost complete 
recovery of ammonium.
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These observations confirmed that a significant 
amount of ammonium produced by urease activity was 
retained by the organism during the 5 min incubation 
studies.
Confirmation of the role of intracellular ammonium 
metabolism in the destruction of the organism was 
demonstrated by enhanced survival of H pylori in 0.2 
mmol/L isocitrate buffer with 50 mmol/L urea compared with 
citrate buffer with 50 mmol/L urea. Isocitric acid differs 
from citrate by only the position of one hydroxyl group 
(Fig 9.5). Isocitric acid is also direct precursor of 
alpha ketoglutarate which is used to incorporate ammonium 
into glutamic acid and other aminoacids required for 
intracellular metabolic processes (Fig 9.4). The survival 
of H pylori when pre-incubated with alpha ketoglutarate 
was also enhanced. The improved survival of H pylori when 
the substrates required for intracellular metabolism of 
ammonium were supplied therefore demonstrated that the 
intracellular metabolism of ammonium was the key to the 
destruction of the organism by its urease activity.
10.4 Helicobacter pylori urease activity
Urease activity is expressed by many micro-organisms 
(192). It is usually a means of scavenging nitrogen from 
urea within the organism's environment. Ureaplasma 
urealyticum urease activity has been linked to proton
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transport and could be used to produce high energy 
intermediates although the organism does not appear to be 
critically dependent on the production of high energy 
intermediates from proton transport linked to ammonium 
accumulation (192).
The Michaelis constant (Km) of the urease enzymes 
produced by other bacteria varies (192). It ranges from
0.12 mmol/L for Spirula maxima to 10.5-71 mmol/L for 
proteus species and up to 130 mmol/L for Bacillus 
pasteurii. The Km of an enzyme is the concentration of 
substrate at which the enzyme will operate at half maximum 
velocity. The Km of an enzyme can also be regarded as a 
measure of the affinity of the enzyme for the substrate. 
Enzymes with low Km values will have a high affinity and 
bind substrate readily at low concentrations while high Km 
values will require higher substrate concentrations for 
effective operation of the enzyme. High urea 
concentrations in the surrounding medium will therefore 
tend to select for enzymes with high Km values. Proteus 
mirabilis which infects the urinary tract exhibits a range 
of Km values from 13-60 mM (252,253). The concentrations 
of urea found in the urine 0.4-0.5 mol/L would allow the 
proteus urease enzymes to operate at or close to maximum 
velocity (192). The Km of H pylori urease is estimated to 
be between 0.2 and 0.7 mmol/L (193,197,254). At the 
concentrations of urea found in gastric juice from 
uninfected individuals (1.0-3.7 mmol/L) the enzyme would 
not operate at maximum velocity. At the concentrations of 
urea (0.5-2.9 mmol/L) found in infected individuals it
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would be impossible for the enzyme to operate at maximum 
velocity. Some bacteria such as Alcaligenes entrophus and 
Klebsiella pneumoniae, use an energy dependent carrier 
mediated uptake mechanism to concentrate urea within the 
cell to increase the amounts available for hydrolysis by 
urease activity (255-257). It is unlikely that H pylori 
possesses a mechanism to concentrate urea within the cell 
as the enzyme appears to be located on the external 
periplasmic membrane surface (201,202). The abundant 
expression of urease activity by H pylori is therefore 
probably due to the fact that the enzyme's activity is 
limited by availability of substrate under normal 
conditions in the stomach.
10.5 Urease activity and ammonium metabolism
Ammonia diffuses across membranes easily when it is 
not protonated. Bacteria tend to leak ammonia which may 
be produced within the cell as a result of deaminase 
activity. In the gastric environment any ammonium from 
within Helicobacter pylori which diffused out of the cell 
would be rapidly protonated by the gastric acid and lost 
to the organism for metabolic purposes. Some bacteria are 
able to conserve ammonium or scavenge it from the 
immediate environment through energy dependent ammonium 
pumps which maintain the intracellular ammonium 
concentration higher than that of the surrounding medium 
(258). It has been shown that H pylori possesses 
deaminase activity and in the absence of urease activity 
will leak ammonium in vitro into the culture media (259).
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This was associated with loss of viability of the organism 
and a rise in pH of the medium.
The abundant expression of urease activity by 
H pylori will result in the production of large amounts of 
ammonia close to the surface of the periplasmic membrane. 
Some ammonia will diffuse from the surface, become 
protonated and cause the observed increase in gastric 
juice ammonium concentration. As the organism has 
abundant urease enzyme activity there may be sufficient 
ammonia produced at the periplasmic membrane to allow the 
diffusion of ammonia down a concentration gradient into 
the cell before it was protonated by the acidity of the 
gastric juice. This would allow the organism to utilise 
ammonium produced from urea by glutamate dehydrogenase 
activity or glutamine synthetase activity. This theory 
could explain the paradoxically protective effect of 
urease activity at low pH and the lethal effects of urease 
activity at pH 6.0.
At low pH the residual urease activity could result 
in intracellular accumulation of sufficient ammonium to 
neutralise the effect of increasing intracellular 
acidity. At pH 6.0 reduced survival may be due to a 
reduced intracellular pH when compared with that in pH 7.0 
buffer. The pKa of the ammonia-ammonium equilibrium is 
9.13 (260). This means that in a buffer system at pH 7.4 
more than 98% of ammonia present would be in the form of 
ammonium ions and less than 2% as ammonia. In a buffer
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system at pH 6.0 almost 100% of ammonia would be in the 
form of ammonium ions. At physiological pH H pylori leaks 
ammonia as the unprotonated 2% diffuses across the cell 
membrane (259). At a lower intracellular pH the rate of 
loss of ammonia by diffusion would be reduced with the 
reduction in amount of free ammonia. H pylori would 
therefore tend to accumulate ammonium ions which might 
swamp its metabolic processes and favour the depletion of 
intracellular alpha ketoglutarate. In addition, at pH
6.0 sufficient urease activity remains to ensure that 
large amounts of ammonia could be produced when high 
concentrations of urea were present.
A reduced intracellular pH might also reduce the 
activity of the enzymes required to produce alpha 
ketoglutarate. Citrate also inhibits isocitrate 
dehydrogenase and thereby further impedes the 
replenishment of alpha ketoglutarate, thereby enhancing 
the accumulation of ammonia (Fig 9.4). Conversely the 
supply of alpha ketoglutarate and isocitrate required for 
the metabolism of ammonium resulted in enhanced survival 
of the organism. The rapid destruction of H pylori during 
the in vitro experiments was therefore due to rapid 
intracellular accumulation of ammonium ions and depletion 
of alpha ketoglutarate.
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10.6 Urease mediated destruction of Helicobacter pylori
and the treatment of duodenal ulcers 
Omeprazole (Astra, Bucks, UK) irreversibly inhibits 
the gastric proton pump and results in a near neutral 
gastric pH. This might approximate to the near neutral in 
vitro conditions in which the organism was destroyed.
Some individuals have been reported to have had 
Helicobacter pylori eradicated when treated with 
omeprazole (204-207). Claims of eradication of H pylori 
by administration of omeprazole are not well substantiated 
as other studies have not shown this effect (208,209). 
Bacterial overgrowth of the stomach during treatment with 
omeprazole has been suggested as the reason for the 
reported differences in the effect of omeprazole. Another 
possible explanation for the contradictory reports of an 
anti-H pylori effect for omeprazole may be differences in 
gastric juice urea concentrations in the subjects 
studied. If omeprazole, by raising gastric juice pH 
caused urease mediated destruction of the organism then a 
high gastric juice urea concentration would be essential. 
If this is the case then the administration of urea to 
subjects during a course of omeprazole might prove 
effective in eradicating the organism.
A lower prevalence of H pylori infection has also 
been found in individuals with chronic renal failure which 
is associated with raised gastric juice urea 
concentrations (5.4-20.8 mmol/L) (247,248). The higher
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gastric juice urea concentrations in patients with chronic 
renal failure would enable the organism's urease enzyme to 
operate at or close to maximum velocity. Higher gastric 
juice ammonium concentrations would also favour increased 
diffusion of the ammonium produced into the organism.
These effects might explain the reduced prevalence of 
infection with H pylori in individuals with chronic renal 
failure.
At present triple therapy to eradicate H pylori is 
not 100% effective and requires a prolonged course of 
treatment (218). Additionally there has been an increase 
in resistance of H pylori to metronidazole. Widespread 
treatment of this common infection would result in 
increasing antibiotic resistance.
Any new therapeutic measures which increase the 
effectiveness of current treatment will prove useful in 
the treatment of this common infection which is one of the 
most important acquired factors in the development of 
duodenal ulcer disease.
If an effective treatment for H pylori was available 
then the benefits could be considerable. Not only is the 
infection present in up to 100% of individuals with 
duodenal ulcer but there is a considerable reserve of 
asymptomatic individuals in the population some of whom 
may go on to develop peptic ulcers. Infection with 
H pylori has also been implicated in the development of 
gastric cancer and any treatment which could result in a 
reduction in the incidence of this malignancy which is
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difficult to treat conventionally would prove to be of 
significant benefit.
10.7 Final Conclusion
The production of ammonium by the organism's urease 
activity is not the cause of the raised plasma gastrin 
concentrations found in individuals with duodenal ulcer 
disease. The urease enzyme of H pylori is used to 
scavenge nitrogen from the urea which diffuses from the 
bloodstream into the gastric juice. The protection of 
the organism by urease activity at low pH is probably due 
to the neutralisation of intracellular acidity by ammonia 
produced by urease activity.
The organism's urease activity can be harnessed to 
detect antral infection by the measurement of the 
urea/ammonium ratio in gastric juice. Urease activity has 
also been harnessed to cause the in vitro metabolic 
destruction of the organism. If the conditions required 
for urease mediated destruction can be achieved in vivo 
then this would represent a significant advance in the 
treatment of peptic ulcer disease.
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